

Cumulative contents

Volumes 78–81 (2006)

Volume 78, Number 1, January 2006

Original articles

- Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease
M. Shahidi, N. Kamangari, S. Ashley, D. Cunningham, A. Horwich (UK) 1
- Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy
Y. Ejima, R. Sasaki, Y. Okamoto, T. Maruta, A. Azumi, Y. Hayashi, Y. Demizu, Y. Ota, T. Soejima, K. Sugimura (Japan) 6
- Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure
C. Ll  cer, M. Delannes, M. Minsat, E. Stoeckle, L. Votron, P. Martel, P. Bonneville, B. Nguyen Bui, C. Chevreau, G. Kantor, N. Daly-Schveitzer, L. Thomas (France) 10
- Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF-   activity
J.M. Akudugu, R.S. Bell, C. Catton, A.M. Davis, A.M. Griffin, B. O'Sullivan, J.N. Waldron, P.C. Ferguson, J.S. Wunder, R.P. Hill (Canada) 17
- Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities
C. Baum, M. Alber, M. Birkner, F. N  sslin (Germany) 27
- 3-D conformal radiotherapy of localized prostate cancer: A subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects
G. Goldner, F. Zimmermann, H. Feldmann, S. Glocker, N. Wachter-Gerstner, H. Geinitz, G. Becker, R. P  tzi, A. Wambersie, M. Bamberg, M. Molls, S. Wachter, R. P  tter (Austria, Germany) 36
- Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer- a phase II study
M. Pinkawa, K. Fischeidick, P. Treusacher, B. Asadpour, B. Gagel, M.D. Piroth, H. Borchers, G. Jakse, M.J. Eble (Germany) 41
- ¹⁹²Ir or ¹²⁵I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: A dosimetric point of view
P. Nickers, B. Thissen, N. Jansen, J.M. Deneufbourg (Belgium) 47
- On-line implant reconstruction in HDR brachytherapy
I.K. Kolkman-Deurloo, W.J.M. de Kruijf, P.C. Levendag (The Netherlands) 53
- Randomized blinded clinical trial of intracoronary brachytherapy with ⁹⁰Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients
B. Syeda, C. Schukro, C. Kirisits, I. Lang, P. Siostrzonek, M. Gottsauner-Wolf, B. Pokrajac, R. Schmid, N. Yahya, R. P  tter, D. Glogar (Austria) 60
- Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
R. P  tter, C. Haie-Meder, E. Van Limbergen, I. Barillot, M.D. Brabandere, J. Dimopoulos, I. Dumas, B. Erickson, S. Lang, A. Nulens, P. Petrow, J. Rownd, C. Kirisits (Austria, France, Belgium, USA) 67
- The EQUAL-ESTRO audit on geometric reconstruction techniques in brachytherapy
A. Rou  , I.H. Ferreira, J. Van Dam, H. Svensson, J.L.M. Venselaar (France, Sweden, The Netherlands) 78
- Comparison of simulator-CT versus simulator fluoroscopy versus surface marking based radiation treatment planning: A prospective study by three-dimensional evaluation
V. Suhag, V. Kaushal, R. Yadav, B.P. Das (India) 84
- Treatment of radiation proctitis with hyperbaric oxygen
K. Jones, A.W. Evans, R.G. Bristow, W. Levin (Canada) 91
- Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: A study of the REACT working group of ESTRO
  .U. Ataman, A. Barrett, T. Filleron, A. Kramar, on behalf of ESTRO-REACT Group (Turkey, UK, France) 95
- Family physicians' perspectives regarding palliative radiotherapy
R.S. Samant, E. Fitzgibbon, J. Meng, I.D. Graham (Canada) 101

Letters to the Editor

Re: Hermann et al., Low testosterone levels and Quality of Life
T. Pickles, G. Duncan, P. Graham (Canada, Australia)

107

Letter to the Editor

S. Kumar, M. Pandey, P. Lal (India)

108

Letter to the Editor

A. Munshi, K.C. Pandey, S.P. Susheela (India)

109

Thoracic radiotherapy for stage IV non-small cell lung cancer

C.-R. Chien, C.-H. Yang (Taiwan, ROC)

110

Response to the letter to the editor

C.D. Biancia (USA)

110

Instructions to Authors

112

Important ESTRO dates

I

Calendar of Events

II

Volume 78, Number 2, February 2006

Special commentary

From IMRT to IGRT: Frontierland or Neverland?

C.C. Ling, E. Yorke, Z. Fuks (USA)

119

Original articles

Influence of connective tissue diseases on the expression of radiation side effects: A systematic review

T. Hölscher, S.M. Bentzen, M. Baumann (Germany, USA)

123

Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988-2002

A. Vulto, M. Louwman, P. Rodrigus, J.W.W. Coebergh (The Netherlands)

131

Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts

L.A. Huxham, A.H. Kyle, J.H.E. Baker, K.L. McNicol, A.I. Minchinton (Canada)

138

Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: A prospective phase II study

P. Lindholm, R. Valavaara, K. Aitasalo, J. Kulmala, J. Laine, L. Elomaa, L. Sillanmäki, H. Minn, R. Grénman (Finland)

146

Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: A retrospective review

S. Mangar, N. Slevin, K. Mais, A. Sykes (UK)

152

Evaluation of underdosage in the external photon beam radiotherapy of glottic carcinoma: Monte Carlo study

S. Spiridovich, L. Papiez, V. Moskvina, P. Desrosiers (USA)

159

Attempts to predict the long-term decrease in lung function due to radiotherapy of non-small cell lung cancer

M. Nielsen, O. Hansen, W. Vach (Denmark)

165

Comparative planning evaluation of intensity-modulated radiotherapy techniques for complex lung cancer cases

S. Yartsev, J. Chen, E. Yu, T. Kron, G. Rodrigues, T. Coad, K. Trenka, E. Wong, G. Bauman, J. Van Dyk (Canada, Australia)

169

A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy

J.-Y. Jin, M. Ajlouni, Q. Chen, F.-F. Yin, B. Movsas (USA)

177

Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations

S. Lang, A. Nulens, E. Briot, C. Kirisits, M. De Brabandere, I. Dumas, J. Dimopoulos, P. Petrow, D. Georg, E. Van Limbergen, C. Haie-Meder, R. Pötter (Austria, Belgium, France)

185

Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer

H. Ishiyama, M. Kitano, T. Satoh, Y. Niibe, M. Uemae, T. Fujita, S. Baba, K. Hayakawa (Japan)

194

Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy

J. Carl, B. Lund, E. Hoekjaer Larsen, J. Nielsen (Denmark)

199

The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators

A.S. Beddar, S. Krishnan, T.M. Briere, X. Wang, M.E. Delclos, M.T. Ballo, P. Das, S. Gould, J.L. Horton, C.H. Crane (USA)

207

Real-time in vivo dosimetry using micro-MOSFET detectors during intraoperative electron beam radiation therapy in early-stage breast cancer

M. Ciocca, V. Piazzini, R. Lazzari, A. Vavassori, A. Luini, P. Veronesi, V. Galimberti, M. Intra, A. Guido, G. Tosi, U. Veronesi, R. Orecchia (Italy)

213

A simple technique for craniospinal radiotherapy in the supine position W.A. Parker, C.R. Freeman (Canada) (Technical note)	217
Recommendations on detectors and quality control procedures for brachytherapy beta sources R.P. Kollaard, W.J.F. Dries, H.J. van Kleffens, T.H.L. Aalbers, H. van der Marel, H.P.A. Marijnissen, M. Piessens, D.R. Schaart, H. de Vroome (The Netherlands, Belgium)	223
Letters to the Editor	
Comment on: Osteopontin as toxic marker Q.-T. Le, H. Cao, A. Koong, A. Giaccia (USA)	230
Response to a letter to the editor by Le et al. regarding: Osteopontin as toxic marker H. Said, A. Katzer, M. Flentje, D. Vordermark (Germany)	230
Important ESTRO dates	I
Calendar of Events	II
 <i>Volume 78, Number 3, March 2006</i>	
Editorial	
Molecular imaging to improve radiotherapy P. Price (UK)	233
Original articles	
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response J.I. Geh, S.J. Bond, S.M. Bentzen, R. Glynne-Jones (UK)	236
Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: Results on survival in the Dutch Bone Metastasis Study Y.M. van der Linden, E. Steenland, H.C. van Houwelingen, W.J. Post, B. Oei, C.A.M. Marijnen, J.W.H. Leer (The Netherlands), for the Dutch Bone Metastasis Study Group	245
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer T. Leong, C. Everitt, K. Yuen, S. Condrón, A. Hui, S.Y.K. Ngan, A. Pitman, E.W.F. Lau, M. MacManus, D. Binns, T. Ackerly, R.J. Hicks (Australia)	254
Individual radiation response of parotid glands investigated by dynamic ¹¹ C-methionine PET S. Buus, C. Grau, O.L. Munk, A. Rodell, K. Jensen, K. Mouridsen, S. Keiding (Denmark)	262
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer K. Saarilahti, M. Kouri, J. Collan, A. Kangasmäki, T. Atula, H. Joensuu, M. Tenhunen (Finland)	270
Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy C. Fiorino, I. Dell'Oca, A. Pierelli, S. Broggi, E. De Martin, N. Di Muzio, B. Longobardi, F. Fazio, R. Calandrino (Italy)	276
Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV)- and planning organs at risk volume (PRV)-margins M. Suzuki, Y. Nishimura, K. Nakamatsu, M. Okumura, H. Hashiba, R. Koike, S. Kanamori, T. Shibata (Japan)	283
Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies X. Geets, J.-F. Daisne, M. Tomsej, T. Duprez, M. Lonnew, V. Grégoire (Belgium)	291
The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires K. Jensen, A.B. Jensen, C. Grau (Denmark)	298
A phase II study of primary reirradiation in squamous cell carcinoma of head and neck J.A. Langendijk, N. Kaspers, C.R. Leemans, P. Doornaert, B.J. Slotman (The Netherlands)	306
Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors E.T. Soisson, W.A. Tomé, G.M. Richards, M.P. Mehta (USA)	313
Comparison of forward planning with automated inverse planning for three-dimensional conformal radiotherapy of non-small cell lung cancer without IMRT (Technical note) R. Mendes, K. Lavrenkov, J.L. Bedford, A. Henrys, S. Ashley, M. Brada (UK)	322
Changes in the respiratory pattern during radiotherapy for cancer in the lung G. Hugo, C. Vargas, J. Liang, L. Kestin, J.W. Wong, D. Yan (USA)	326
Importing measured field fluences into the treatment planning system to validate a breathing synchronized DMLC-IMRT irradiation technique D. Verellen, K. Tournel, N. Linthout, G. Soete, T. Wauters, G. Storme (Belgium)	332

Prediction of lung tumour position based on spirometry and on abdominal displacement: Accuracy and reproducibility J.D.P. Hoisak, K.E. Sixel, R. Tirona, P.C.F. Cheung, J.-P. Pignol (Canada)	339
Photon pencil kernel parameterisation based on beam quality index T. Nyholm, J. Olofsson, A. Ahnesjö, M. Karlsson (Sweden)	347
Important ESTRO dates	I
Calendar of Events	II

Volume 79, Number 1, April 2006

Original articles

The role of whole pelvic radiotherapy in locally advanced prostate cancer P. Dirix, K. Haustermans, S. Junius, R. Withers, R. Oyen, H. Van Poppel (Belgium, USA)	1
Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck V. Grégoire, A. Eisbruch, M. Hamoir, P. Levendag (Belgium, USA, The Netherlands)	15
Staging of nasopharyngeal carcinoma investigated by magnetic resonance imaging J.-C. Lu, B.-Q. Wei, W.-Z. Chen, P.-D. Qian, Y.-Q. Zhang, Q. Wei, W.-W. Cha, F. Li, M. Ni (China)	21
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: A study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG) P.M.L. Teo, S.F. Leung, S.Y. Tung, B. Zee, J.S.T. Sham, A.W.M. Lee, W.H. Lau, W.H. Kwan, T.W. Leung, D. Chua, W.M. Sze, J.S.K. Au, K.H. Yu, S.K. O, D. Kwong, T.K. Yau, S.C.K. Law, W.K. Sze, G. Au, A.T.C. Chan (China)	27
A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas J.A. Medina, A. Rueda, A. Sacchetti de Pasos, J. Contreras, M. Cobo, P. Moreno, M. Benavides, A. Villanueva, E. Alba (Spain)	34
Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation M.R. Vergeer, P. Doornaert, C.R. Leemans, J. Buter, B.J. Slotman, J.A. Langendijk (The Netherlands)	39
Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration S. Brooker, S. Martin, A. Pearson, D. Bagchi, J. Earl, L. Gothard, E. Hall, L. Porter, J. Yarnold (UK, USA)	45
Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial P.A. Coucke, M. Notter, B. Stamm, M. Matter, F. Fasolini, R. Schlumpf, O. Matzinger, H. Bouzourene (Canada, Switzerland)	52
Adverse effect of a distended rectum in intensity-modulated radiotherapy (IMRT) treatment planning of prostate cancer M. Guckenberger, F. Pohl, K. Baier, J. Meyer, D. Vordermark, M. Flentje (Germany)	59
Radiation exposure after permanent prostate brachytherapy F. Cattani, A. Vavassori, A. Polo, E. Rondi, R. Cambria, R. Orecchia, G. Tosi (Italy, Spain)	65
Effect of random seed placement error in permanent transperineal prostate seed implant M. Bues, E.J. Holupka, P. Meskill, I.D. Kaplan (USA)	70
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study A. Bruna, P. Gastelblum, L. Thomas, O. Chapet, M.A. Bollet, J.-M. Ardiet, J.-P. Gérard, D. Peiffert (France, Belgium)	75
3D conformal HDR-brachy- and external beam therapy plus simultaneous Cisplatin for high-risk cervical cancer: Clinical experience with 3 year follow-up R. Pötter, J. Dimopoulos, B. Bachtary, G. Sissolak, B. Klos, A. Rheinthal, C. Kirisits, T.-H. Knocke-Abulesz (Austria)	80
Geometric stability of intracavitary pulsed dose rate brachytherapy monitored by in vivo rectal dosimetry K. Tanderup, J.J. Christensen, J. Granfeldt, J.C. Lindegaard (Denmark)	87
Clinical application of a repositioning scheme, using gold markers and electronic portal imaging F. Van den Heuvel, J. Fugazzi, E. Seppi, J.D. Forman (Belgium, USA)	94
Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode D. Vetterli, S. Thalmann, F. Behrensmeier, L. Kemmerling, E.J. Born, R. Mini, R.H. Greiner, D.M. Aebbersold (Switzerland)	101
Molecular verification of stereotactic radiotherapy in rats using ATMP51981 immunofluorescence T.B. Brunner, A. Ernst-Stecken, I. Jeske, G.G. Grabenbauer, R. Sauer, L. Distel (Germany)	109
A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning H.B. Honoré, S.M. Bentzen (Denmark, USA)	115
More optimal dose distributions for moving lung tumours: A planning study B.C.J. Cho, T. Craig (Canada)	122

Monte Carlo dosimetric evaluation of high energy vs low energy photon beams in low density tissues M.F. Tsiakalos, S. Stathakis, G.A. Plataniotis, C. Kappas, K. Theodorou (Greece)	131
Important ESTRO dates	I
Calendar of Events	II
 <i>Volume 79, Number 2, May 2006</i>	
Editorial	
Cervical cancer: Treatment challenges in the developing world G. Thomas (Canada)	139
Original articles	
Prognostic value of response to external radiation in stage IIIB cancer cervix in predicting clinical outcomes: A retrospective analysis of 556 patients from India E.P. Saibishkumar, F.D. Patel, S.C. Sharma, G. Karunanidhi, S. Ghoshal, V. Kumar, R. Kapoor (India)	142
Loco-regional recurrence after mastectomy in high-risk breast cancer—risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials H.M. Nielsen, M. Overgaard, C. Grau, A.R. Jensen, J. Overgaard (Denmark)	147
Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients A. Courdi, C. Ortholan, J.-M. Hannoun-Lévi, J.-M. Ferrero, R. Largillier, C. Balu-Maestro, C. Chapellier, F. Ettore, I. Birtwisle-Peyrottes (France)	156
Intensity-modulated radiotherapy of breast cancer using direct aperture optimization B. van Asselen, M. Schwarz, C. van Vliet-Vroegindeweij, J.V. Lebesque, B.J. Mijnheer, E.M.F. Damen (The Netherlands)	162
Patient set-up verification by infrared optical localization and body surface sensing in breast radiation therapy M.F. Spadea, G. Baroni, M. Riboldi, B. Tagaste, C. Garibaldi, R. Orecchia, A. Pedotti (Italy)	170
Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification K.-i. Sakata, N. Fuwa, T. Kodaira, K. Aratani, H. Ikeda, M. Takagi, M. Nishio, M. Satoh, S. Nakamura, H. Satoh, M. Hareyama (Japan)	179
The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer D. Ash, B. Al-Qaisieh, D. Bottomley, B. Carey, J. Joseph (UK)	185
Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom M. De Brabandere, C. Kirisits, R. Peeters, K. Haustermans, F. Van den Heuvel (Belgium)	190
The impact of dental metal artifacts on head and neck IMRT dose distributions Y. Kim, W.A. Tomé, M. Bal, T.R. McNutt, L. Spies (USA)	198
Does 4 MV perform better compared to 6 MV in the presence of air cavities in the head and neck region? A.L. Petoukhova, C.H.J. Terhaard, H. Welleweerd (The Netherlands)	203
Application of the quality index methodology for dosimetric verification of build-up effect beyond air-tissue interface in treatment planning system algorithms S. Caneva, M.F. Tsiakalos, S. Stathakis, S. Zefkili, A. Mazal, J.-C. Rosenwald (France, Greece) (Technical note)	208
Anatomy changes in radiotherapy detected using portal imaging L.N. McDermott, M. Wendling, J.-J. Sonke, M. van Herk, B.J. Mijnheer (The Netherlands)	211
A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons M.F. Chan, C.S. Chui, Y. Song, C. Burman, E. Yorke, C. Della-Biancia, K.E. Rosenzweig, K. Schupak (USA)	218
Gamma histograms for radiotherapy plan evaluation E. Spezi, D.G. Lewis (UK)	224
Partial volume rat lung irradiation: The protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic A.R. Langan, M.A. Khan, I.W.T. Yeung, J. Van Dyk, R.P. Hill (Canada)	231
The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome M.C. Wergin, M. Roos, N. Inteeworn, D. Luluhová, K. Allemann, B. Kaser-Hotz (Switzerland)	239
Important ESTRO dates	I
Calendar of Events	II
 <i>Volume 79, Number 3, June 2006</i>	
Editorial	
Dose painting: Art or science? K. Tanderup, D.R. Olsen, C. Grau (Denmark, Norway)	245

Original articles

- ¹⁸F]fluoro-deoxy-glucose positron emission tomography (¹⁸F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer
B. Vanderstraeten, W. Duthoy, W. De Gersem, W. De Neve, H. Thierens (Belgium) 249
- Guidelines for primary radiotherapy of patients with prostate cancer
D. Boehmer, P. Maingon, P. Poortmans, M.-H. Baron, R. Miralbell, V. Remouchamps, C. Scrase, A. Bossi, M. Bolla, on behalf of the EORTC radiation oncology group (Germany, France, The Netherlands, Switzerland, Belgium, UK) 259
- Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
T. Girinsky, R. van der Maazen, L. Specht, B. Aleman, P. Poortmans, Y. Lievens, P. Meijnders, M. Ghalibafian, J. Meerwaldt, E. Noordijk, on behalf of the EORTC-GELA Lymphoma Group (France, The Netherlands, Denmark, Belgium) 270
- Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases
S. Kaasa, E. Brenne, J.-A. Lund, P. Fayers, U. Falkmer, M. Holmberg, M. Lagerlund, O. Bruland (Norway, UK, Sweden) 278
- Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer
C. Duisters, H. Beurskens, S. Nijsten, M. Starmans, S. Wanders, T. Verschueren, P. Lambin, A. Minken, D. De Ruyscher (The Netherlands) (Technical note) 285
- The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON
R.A. Jonathan, K.I.E.M. Wijffels, W. Peeters, P.C.M. de Wilde, H.A.M. Marres, M.A.W. Merks, E. Oosterwijk, A.J. van der Kogel, J.H.A.M. Kaanders (The Netherlands) 288
- A dosimetric analysis of interstitial intensity modulated implants for pelvic recurrences, base of tongue and orbita tumors with specific references to the ICRU-58
F.-A. Siebert, T. Born, S. Häring, F. Seefeld, G. Kovács (Germany) 298
- Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer
E. Senkus-Konefka, E. Naczka, I. Borowska, A. Badzio, J. Jassem (Poland) 304
- CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning
Y.M. Kirova, V. Servois, F. Campana, R. Dendale, M.A. Bollet, F. Laki, N. Fournier-Bidoz, A. Fourquet (France) 310
- Clinical experience with the MammoSite[®] radiation therapy system for brachytherapy of breast cancer: Results from an international phase II trial
P. Niehoff, C. Polgár, H. Ostertag, T. Major, Z. Sulyok, B. Kimmig, G. Kovács (Germany, Hungary) 316
- Dosimetric comparisons between high dose rate interstitial and MammoSite[™] balloon brachytherapy for breast cancer
T. Major, P. Niehoff, G. Kovács, J. Fodor, C. Polgár (Hungary, Germany) 321
- ¹⁹²Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial
P. Nickers, L. Coppens, J. de Leval, N. Jansen, J.-M. Deneufbourg (Belgium) 329
- Variability of bladder filling in patients receiving radical radiotherapy to the prostate
Ú.M. O'Doherty, H.A. McNair, A.R. Norman, E. Miles, S. Hooper, M. Davies, N. Lincoln, J. Balyckyi, P. Childs, D.P. Dearnaley, R.A. Huddart (UK) 335
- Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer
H. Geinitz, F.B. Zimmermann, R. Thamm, C. Erber, T. Müller, M. Keller, R. Busch, M. Molls (Germany) 341
- Notes on the construction of solid-state detectors
C. McKerracher, D.I. Thwaites (UK) (Technical note) 348
- Letters to the Editor**
- An anaphylactoid reaction from amifostine
A. Lin, T.S. Lawrence (USA) 352
- Consideration about axillary nodes and arm position
S. Pergolizzi, E.G. Russi (Italy) 352
- Author's reply
D.B. Mansur (USA) 353
- Important ESTRO dates** I
- Calendar of Events** II
- Volume 80, Number 1, July 2006
- Editorial**
- Distal rectal cancer: Sphincter-sparing is also a challenge for the radiation oncologist
J.-F. Bosset (France) 1

Review articles

- Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials
K. Bujko, L. Kepka, W. Michalski, M.P. Nowacki (Poland) 4

- The role of radiation therapy in malignant pleural mesothelioma: A systematic review
Y.C. Ung, E. Yu, C. Falkson, A.E. Haynes, D. Stys-Norman, W.K. Evans, and the Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (Canada) 13

Original articles

- Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies
P. Georg, D. Georg, M. Hillbrand, C. Kirisits, R. Pötter (Austria) 19

- A pilot study of accelerated preoperative hyperfractionated pelvic irradiation with or without low-dose preoperative prophylactic liver irradiation in patients with locally advanced rectal cancer
R. Suwinski, J. Wydmanski, I. Pawelczyk, J. Starzewski (Poland) 27

- Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study
T. Hehr, J. Classen, S. Welz, U. Ganswindt, H. Scheithauer, A. Koitschev, M. Bamberg, W. Budach (Germany) 33

- Manually after-loaded ¹⁹²Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer
C. Nutting, N. Horlock, R. A'Hern, A. Searle, J. M. Henk, P. Rhys-Evans, K. Harrington (United Kingdom) 39

- Assessment of ¹⁸F PET signals for automatic target volume definition in radiotherapy treatment planning
J.B. Davis, B. Reiner, M. Huser, C. Burger, G. Székely, I.F. Ciernik (Switzerland) 43

- Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer
L.-F. de Geus-Oei, J.H.A.M. Kaanders, L.A.M. Pop, F.H.M. Corstens, W.J.G. Oyen (The Netherlands) 51

- Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer
F. Guedea, F. Aguilo, A. Polo, S. Langley, R. Laing, A. Henderson, S. Aaltomaa, V. Kataja, J. Palmgren, F. Bladou, N. Salem, G. Gravis, A. Losa, G. Guazzoni, L. Nava, (Spain, UK, Finland, France, Italy) 57

- High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer
Y. Yoshioka, K. Konishi, R.-J. Oh, I. Sumida, H. Yamazaki, S. Nakamura, K. Nishimura, N. Nonomura, A. Okuyama, T. Inoue (Japan) 62

- Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants
B.R. Pieters, J.N.B. van der Grient, L.E.C.M. Blank, K. Koedooder, M.C.C.M. Hulshof, T.M. de Reijke (The Netherlands) (Technical note) 69

- A new robotic needle insertion method to minimise attendant prostate motion
V. Lagerburg, M.A. Moerland, M. van Vulpen, J.J.W. Lagendijk (The Netherlands) 73

- Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity
G. Soete, S. Arcangeli, G. De Meerleer, V. Landoni, V. Fonteyne, G. Arcangeli, W. De Neve, G. Storme, (Belgium, Italy) 78

- A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer
A. Rollo Moore, A.P. Jim Warrington, E.G.A. Aird, A. Margaret Bidmead, D.P. Dearnaley (UK) (Technical note) 82

- Fast, daily linac verification for segmented IMRT using electronic portal imaging
S.C. Vieira, R.A. Bolt, M.L.P. Dirkx, A.G. Visser, B.J.M. Heijmen (The Netherlands) 86

- Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients
I. Sekine, M. Sumi, Y. Ito, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, T. Kodama, N. Saijo, T. Tamura (Japan) 93

- A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy
L.P. Muren, A.T. Redpath, D. McLaren, J. Rørvik, O.J. Halvorsen, J. Høstmark, A. Bakke, D. Thwaites, O. Dahl, (Norway, UK) 98

Letters to the Editor

- Sparing submandibular gland by IMRT
E.P. Saibishkumar, N. Jha (Canada) 106

Erratum

- Erratum to "Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer" [Radiother. Oncol. 78 (2006) 270–275]
K. Saarilahti, M. Kouri, J. Collan, A. Kangasmäki, T. Atula, H. Joensuu, M. Tenhunen (Finland) 107

Important ESTRO dates

I

Calendar of Events

II

Volume 80, Number 2, August 2006

Editorial

Bridging gaps in translational radiation oncology
J. Bernier, J. Overgaard (Switzerland, Denmark)

109

Review

Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy
M. Krause, D. Zips, H.D. Thames, J. Kummermehr, M. Baumann (Germany, USA)

112

Original articles

The prognostic value of pimonidazole and tumour pO_2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study

M. Nordsmark, J. Loncaster, C. Aquino-Parsons, S.-C. Chou, V. Gebiski, C. West, J.C. Lindegaard, H. Havsteen, S.E. Davidson, R. Hunter, J.A. Raleigh, J. Overgaard (Denmark, UK, Canada, USA, Australia)

123

Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer

A. Fyles, M. Milosevic, M. Pintilie, A. Syed, W. Levin, L. Manchul, R.P. Hill (Canada)

132

The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy

R.E. Durand, C. Aquino-Parsons (Canada)

138

Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1

H. De Schutter, B. Barbé, M. Spaepen, A.C. Begg, A. Balm, V. Gregoire, K. Haustermans, P. Mahy, V. Vander Poorten, S. Nuyts (Belgium, The Netherlands)

143

Combined uptake of [^{18}F]FDG and [^{18}F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients

D. Thorwarth, S.-M. Eschmann, F. Holzner, F. Paulsen, M. Alber (Germany)

151

Imaging hypoxia after oxygenation-modification: Comparing [^{18}F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors

E.G.C. Troost, P. Laverman, J.H.A.M. Kaanders, M. Philippens, J. Lok, W.J.G. Oyen, A.J. van der Kogel, O.C. Boerman, J. Bussink (The Netherlands)

157

Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models

S. Lukacova, J. Overgaard, J. Alsner, M.R. Horsman (Denmark)

165

Molecular responses of rectal cancer to preoperative chemoradiation

A. Debucquoy, L. Goethals, K. Geboes, S. Roels, W.H. Mc Bride, K. Haustermans (Belgium, USA)

172

Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin

I. Eke, V. Sandfort, A. Mischkus, M. Baumann, N. Cordes (Germany)

178

Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases

U. Raju, H. Ariga, M. Koto, X. Lu, J. Pickett, D. Valdecana, K.A. Mason, L. Milas (USA)

185

CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors

K.A. Mason, R. Neal, N. Hunter, H. Ariga, K. Ang, L. Milas (USA)

192

Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling

R. Handrick, A. Rübel, H. Faltin, H. Eibl, C. Belka, V. Jendrosseck (Germany)

199

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours

S.R. Vink, J.H.M. Schellens, J.H. Beijnen, H. Sindermann, J. Engel, R. Dubbelman, G. Moppi, M.J.X. Hillebrand, H. Bartelink, M. Verheij (The Netherlands, Germany)

207

TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy

E.H.J. Wissink, I. Verbrugge, S.R. Vink, M.B. Schader, U. Schaefer, H. Walczak, J. Borst, M. Verheij (The Netherlands, Germany)

214

Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays

D. Klovov, S.M. MacPhail, J.P. Banáth, J.P. Byrne, P.L. Olive (Canada)

223

Radiation-induced effects on gene expression: An in vivo study on breast cancer

Å. Helland, H. Johnsen, C. Frøyland, H.B.K. Landmark, A.B. Sætersdal, M.M. Holmen, T. Gjertsen, J.M. Nesland, W. Ottestad, S. S. Jeffrey, L.O. Ottestad, O.K. Rodningen, G. Sherlock, A.-L. Børresen-Dale (Norway, USA)

230

Lymphoblastoid cell lines differing in p53 status show clear differences in basal gene expression with minor changes after irradiation

O. Zschenker, K. Borgmann, T. Streichert, I. Meier, A. Wrona, E. Dikomey (Germany)

236

Radiation-induced damage to mouse urothelial barrier

J. Jaal, W. Dörr (Germany)

250

Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy

S.S. Korreman, A.N. Pedersen, M. Josipović, L.R. Aarup, T. Juhler-Nøttrup, L. Specht, H. Nyström (Denmark)

257

Intensity modulated photon and proton therapy for the treatment of head and neck tumors M. Steneker, A. Lomax, U. Schneider (Switzerland, The Netherlands)	263
Comparison of advanced irradiation techniques with photons for benign intracranial tumours L. Cozzi, A. Clivio, G. Bauman, S. Cora, G. Nicolini, R. Pellegrini, E. Vanetti, S. Yartsev, A. Fogliata (Switzerland, Italy, Canada)	268
Important ESTRO dates	I
Calendar of Events	II
<i>Volume 80, Number 3, September 2006</i>	
Original articles	
Risk, society and system failure P. Scalliet (Belgium)	275
Risk analysis in radiation treatment: Application of a new taxonomic structure E.U. Ekaette, R.C. Lee, D.L. Cooke, K.-L. Kelly and P.B. Dunscombe (Canada)	282
Clinical implementation of MOSFET detectors for dosimetry in electron beams E.J. Bloemen-van Gurp, A.W.H. Minken, B.J. Mijnheer, C.J.G. Dehing-Oberye and P. Lambin (The Netherlands)	288
Feasibility study of using MOSFET detectors for in vivo dosimetry during permanent low-dose-rate prostate implants J.E. Cygler, A. Saoudi, G. Perry, C. Morash and C.E. (Canada)	296
Aspiration rate following chemoradiation for head and neck cancer: An underreported occurrence N.P. Nguyen, C. Frank, C.C. Moltz, P. Vos, H.J. Smith, P.V. Bhamidipati, U. Karlsson, P.D. Nguyen, A. Alfieri, L.M. Nguyen, C. Lemanski, W. Chan, S. Rose and S. Sallah (USA, France, Greece)	302
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial D. De Ruyscher, R.-H. Bremer, F. Koppe, S. Wanders, E. van Haren, M. Hochstenbag, W. Geeraedts, C. Pitz, J. Simons, G. ten Velde, J. Dohmen, G. Snoep, L. Boersma, T. Verschueren, A. van Baardwijk, C. Dehing, M. Pijls, A. Minken and P. Lambin (The Netherlands)	307
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer – A retrospective analysis R. Bartsch, S. Fromm, M. Rudas, C. Wenzel, S. Harbauer, K. Roessler, K. Kitz, G.G. Steger, H.-D. Weitmann, R. Poetter, C.C. Zielinski and K. Dieckmann (Austria)	313
Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05) D.E. Roos, A. Wirth, B.H. Burmeister, N.A. Spry, K.J. Drummond, J.A. Beresford and B.E. McClure (Australia) (Short communication)	318
Palliative treatment of Erdheim–Chester disease with radiotherapy: A Rare Cancer Network study R.C. Miller, S. Villà, S. Kamer, D. Pasquier, P. Poortmans, O. Micke and T.G. Call (United States, Spain, Turkey, France, The Netherlands, Germany) (Short communication)	323
Esophageal cancer: Determination of internal target volume for conformal radiotherapy F. Lorchel, J.L. Dumas, A. Noël, D. Wolf, J.F. Bosset and P. Aletti (France)	327
Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes O. Chapet, M. Khodri, P. Jalade, D. N'guyen, I. Flandin, A. D'hombres, P. Romestaing and F. Mornex (France)	333
Respiratory correlated segment reconstruction algorithm towards four-dimensional radiation therapy using carbon ion beams S. Mori, M. Endo, R. Kohno, H. Asakura, K. Kohno, T. Yashiro, S. Komatsu, S. Kandatsu and M. Baba (Japan)	341
Planning organ at risk volume margins for organ motion of the intestine L.B. Hysing, Y. Kvinnslund, H. Lord and L.P. Muren (Norway, UK)	349
Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397) S.A. Mangar, M.R. Sydes, H.L. Tucker, J. Coffey, S.A. Sohaib, S. Gianolini, S. Webb, V.S. Khoo, MRC RT01 Trial Management Group and D.P. Dearnaley (UK)	355
Emptying the rectum before treatment delivery limits the variations of rectal dose–volume parameters during 3DCRT of prostate cancer M. Stasi, F. Munoz, C. Fiorino, M. Pasquino, B. Baiotto, P. Marini, G. Malinverni, R. Valdagni and P. Gabriele (Italy)	363
Setup accuracy of stereoscopic X-ray positioning with automated correction for rotational errors in patients treated with conformal arc radiotherapy for prostate cancer G. Soete, D. Verellen, K. Tournel and G. Storme (Belgium)	371
A comparison of prostate IMRT and helical tomotherapy class solutions G. Rodrigues, S. Yartsev, J. Chen, E. Wong, D. D'Souza, M. Lock, G. Bauman, G. Grigorov and T. Kron (Canada) (Technical note)	374
Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy G.J. Meijer, H.A. van den Berg, C.W. Hurkmans, P.E. Stijns and J.H. Weterings (The Netherlands)	378

A separated primary and scatter model for independent dose calculation of intensity modulated radiotherapy C.R. Baker, R. Clements, A. Gately and G.J. Budgell (UK)	385
New shielding materials for clinical electron beams M. Tajiri, Y. Tokiya, J. Uenishi, M. Sunaoka and K. Watanabe (Japan) (Technical note)	391
Letters to the Editors	
A simple technique for craniospinal radiotherapy in the supine position G. Bauman, E. Wong, K. Trenka and D. Scott (Canada)	394
Letter to the editor C. Cousins and J.-M. Cosset (UK)	395
Important ESTRO dates	I
Calendar of Events	II

Volume 81, Number 1, October 2006

Systematic review

Re-irradiation in the management of isolated neck recurrences: Current status and recommendations S. Chopra, T. Gupta, J.P. Agarwal, A. Budrukkar, S. Ghosh-Laskar, K. Dinshaw (India)	1
---	---

Original articles

Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group N.K. Gogna, J.H.L. Matthews, S.L. Turner, H. Mameghan, G.M. Duchesne, N. Spry, M.P. Berry, J. Keller, L. Tripcony (Australia, New Zealand)	9
Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity A. Ernst-Stecken, O. Ganslandt, U. Lambrecht, R. Sauer, G. Grabenbauer (Germany)	18
Impact of target point deviations on control and complication probabilities in stereotactic radiosurgery of AVMs and metastases H. Treuer, M. Kocher, M. Hoevels, S. Hunsche, K. Luyken, M. Maarouf, J. Voges, R.-P. Müller, V. Sturm (Germany)	25
Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium A.-S. Carret, U. Tabori, B. Crooks, J. Hukin, I. Odame, D.L. Johnston, D.L. Keene, C. Freeman, E. Bouffet, On behalf of the Canadian Pediatric Brain Tumour Consortium (CPBTC) (Canada)	33
Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A Rare Cancer Network study E. Ozyar, U. Selek, S. Laskar, O. Uzel, Y. Anacak, M. Ben-Arush, S. Polychronopoulou, F. Akman, S.L. Wolden, S. Sarhan, R.C. Miller, M. Ozsahin, U. Abacioğlu, M. Martin, M. Caloglu, L. Scandolaro, E. Szutowicz, I.L. Atahan (Turkey, India, Israel, Greece, USA, Switzerland, Spain, Italy, Poland)	39
Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer L. Guldner, N. Haddy, F. Pein, I. Diallo, A. Shamsaldin, M. Dahan, J. Lebidois, P. Merlet, E. Villain, D. Sidi, O. Sakiroglu, O. Hartmann, D. Leftakopoulos, F. de Vathaire (France)	47
Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study H. Ishikawa, H. Tsuji, T. Kamada, T. Yanagi, J.-E. Mizoe, T. Kanai, S. Morita, M. Wakatsuki, J. Shimazaki, H. Tsujii, Working Group for Genitourinary Tumors (Japan)	57
Image-guided intensity-modulated radiation therapy for gallbladder carcinoma C.D. Fuller, C.R. Thomas Jr., A. Wong, S.X. Cavanaugh, B.J. Salter, T.S. Herman, M. Fuss (USA)	65
An "in silico" clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients G. Bosmans, J. Buijsen, A. Dekker, M. Velders, L. Boersma, D. De Ruyscher, A. Minken, P. Lambin (The Netherlands)	73
Dosimetric comparison of helical tomotherapy treatment and step-and-shoot intensity-modulated radiotherapy of retroperitoneal sarcoma R.D. Pezner, A. Liu, C. Han, Y.-J. Chen, T.E. Schultheiss, J.Y.C. Wong (USA)	81
Dosimetric verification of 6 and 18 MV intensity modulated photon beams using a dedicated fluoroscopic electronic portal imaging device (EPID) A.F. Monti, G. Frigerio (Italy)	88
Dosimetric comparison of stereotactic body radiotherapy in different respiration conditions: A modeling study K. Kontriso, M. Stock, K. Dieckmann, J. Bogner, R. Pötter, D. Georg (Austria)	97
Dose optimisation in single plane interstitial brachytherapy K. Tanderup, T.P. Hellebust, H.B. Honoré, S.K. Nielsen, D.R. Olsen, C. Grau, J.C. Lindegaard (Denmark, Norway)	105
Preclinical safety and antitumor efficacy of insulin combined with irradiation B.F. Jordan, N. Beghein, N. Crokart, C. Baudelet, V. Grégoire, B. Gallez (Belgium)	112

Important ESTRO dates

I

Calendar of Events

II

Volume 81, Number 2, November 2006

Editorial

Tumour hypoxia – A characteristic feature with a complex molecular background

J.G. Eriksen and M.R. Horsman (Denmark)

119

Original articles

Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies

A. Yaromina, D. Zips, H.D. Thames, W. Eicheler, M. Krause, A. Rosner, M. Haase, C. Petersen, J.A. Raleigh, V. Quennet, S. Walenta, W. Mueller-Klieser and M. Baumann (Germany, USA)

122

Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice

V. Quennet, A. Yaromina, D. Zips, A. Rosner, S. Walenta, M. Baumann and W. Mueller-Klieser (Germany)

130

A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma—Trans Tasman Radiation Oncology Group (TROG) Study 96.06

B.H. Burmeister, B.M. Smithers, E. Burmeister, K. Baumann, S. Davis, H. Krawitz, C. Johnson and N. Spry (Australia, New Zealand)

136

Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer

G.B. van den Broek, A.J.M. Balm, M.W.M. van den Brekel, M. Hauptmann, J.H. Schornagel and C.R.N. Rasch (The Netherlands)

143

Dynamic intensity-modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer

J. Krayenbuehl, J.B. Davis and I.F. Ciernik (Switzerland)

151

Influence of intravenous contrast agent on dose calculations of intensity modulated radiation therapy plans for head and neck cancer

Y. Choi, J.-K. Kim, H.-S. Lee, W.-J. Hur, Y.-S. Hong, S. Park, K. Ahn and H. Cho (South Korea)

158

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

A.J. Khan, P.S. Mehta, T.W. Zusag, P.D. Bonomi, L. Penfield Faber, S. Shott and R.A. Abrams (USA) (Short communication)

163

Dosimetric pre-treatment verification of IMRT using an EPID; clinical experience

M. van Zijtveld, M.L.P. Dirkx, H.C.J. de Boer and B.J.M. Heijmen (The Netherlands)

168

Clinical assessment of the use of the Sonarray system for daily prostate localization

K. Peignaux, G. Truc, I. Barillot, A. Ammor, S. Naudy, G. Créhange and P. Maingon (France) (Technical note)

176

Prostate volume determination: Differential volume measurements comparing CT and TRUS

K.M. Kälkner, G. Kubicek, J. Nilsson, M. Lundell, S. Levitt and S. Nilsson (Sweden, USA)

179

Motion and shape change when using an endorectal balloon during prostate radiation therapy

L.E. Court, A.V. D'Amico, D. Kadam and R. Cormack (USA)

184

Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning

T.B. Brunner, U. Baum, G.G. Grabenbauer, R. Sauer and U. Lambrecht (Germany)

190

Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/blb mouse

M. Machtay, A. Scherpereel, J. Santiago, J. Lee, J. McDonough, P. Kinniry, E. Arguiri, V.V. Shuvaev, J. Sun, K. Cengel, C.C. Solomides and M. Christofidou-Solomidou (USA)

196

The impact of peak-kilovoltage settings on heterogeneity-corrected photon-beam treatment plans

R.L. Kendall, K.A. Gifford and S.M. Kirsner (USA) (Technical note)

206

Review

Practical integration of [¹⁸F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC):

The technical basis, ICRU-target volumes, problems, perspectives

U. Nestle, S. Kremp and A.-L. Grosu (Germany)

209

Important ESTRO dates

I

Calendar of Events

II

Volume 81, Number 3, December 2006

Special commentary

Opening lecture of the 25th annual meeting, ESTRO, Leipzig. Expensive new therapy and finite resources: An ethical dilemma for doctors and scientists

H.J. Meyer (Germany)

227

Editorial

Antiprotons for radiotherapy?

E.J. Hall (USA)

231

Original articles

The biological effectiveness of antiproton irradiation

M.H. Holzscheiter, N. Bassler, N. Agazaryan, G. Beyer, E. Blackmore, J.J. DeMarco, M. Doser, R.E. Durand, O. Hartley, K.S. Iwamoto, H.V. Knudsen, R. Landua, C. Maggiore, W.H. McBride, S.P. Møller, J. Petersen, L.D. Skarsgard, J.B. Smathers, T.D. Solberg, U.I. Uggerhøj, S. Vranjes, H.R. Withers, M. Wong and B.G. Wouters (USA, Denmark, Switzerland, Canada, Serbia and Montenegro, The Netherlands)

233

Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons

D.C. Weber, A.W. Chan, S. Lessell, J.F. McIntyre, S.I. Goldberg, M.R. Bussiere, M.M. Fitzek, A.F. Thornton and T.F. DeLaney (USA, Switzerland)

243

Comparison of dose–volume histograms of IMRT treatment plans for ethmoid sinus cancer computed by advanced treatment planning systems including Monte Carlo

L. Paelinck, B. De Smedt, N. Reynaert, M. Coghe, W. De Gersem, C. De Wagter, B. Vanderstraeten, H. Thierens and W. De Neve (Belgium)

250

Individual differences in chromosomal aberrations after *in vitro* irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients

L.V.R. Distel, S. Neubauer, U. Keller, C.N. Sprung, R. Sauer and G.G. Grabenbauer (Germany, Australia)

257

Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer

J.D. Bradley, A.N. Nofal, I.M. El Naqa, W. Lu, J. Liu, J. Hubenschmidt, D.A. Low, R.E. Drzymala and D. Khullar (USA)

264

Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer

C. Kirisits, S. Lang, J. Dimopoulos, K. Oechs, D. Georg and R. Pötter (Austria)

269

CT-guided intensity-modulated radiotherapy for bladder cancer: Isocentre shifts, margins and their impact on target dose

A.T. Redpath and L.P. Muren (UK, Denmark)

276

Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer

M. Pinkawa, J. Siluscheck, B. Gagel, C. Demirel, B. Asadpour, R. Holy and M.J. Eble (Germany)

284

Prostate displacement kit: Reducing the radiation dose to the rectum

K.M. Kälkner, J. Nilsson, M. Lundell, S. Levitt and S. Nilsson (Sweden, USA) (Technical note)

291

Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs)

B.A. Jereczek-Fossa, F. Cattani, A. D'Onofrio, R. Cambria, A. Kowalczyk, A. Corallo, A. Vavassori, D. Zerini, G. Battista Ivaldi, O. DeCobelli and R. Orecchia (Italy, Poland)

294

Importance of the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostate brachytherapy

O. Tanaka, S. Hayashi, K. Sakurai, M. Matsuo, M. Nakano, S. Maeda, H. Hoshi and T. Deguchi (Japan)

303

High density dental materials and radiotherapy planning: Comparison of the dose predictions using superposition algorithm and fluence map Monte Carlo method with radiochromic film measurements

S. Spirydovich, L. Papiez, M. Langer, G. Sandison and V. Thai (USA)

309

Dosimetric verification of the anisotropic analytical algorithm for radiotherapy treatment planning

C.M. Bragg and J. Conway (UK)

315

A core curriculum for RTTs (radiation therapists/radiotherapy radiographers) designed for developing countries under the auspices of the international atomic energy agency (IAEA)

M. Coffey, P. Engel-Hills, M. El-Gantiry, N. Benjaafar, K. Wilkinson and B. Vikram (South Africa, Egypt, Morocco, USA)

324

Cumulative Contents

326

Cumulative Author Index

338

Cumulative Subject Index

354

Important ESTRO Dates

I

Calendar of Events

II

Cumulative author index

Volumes 78–81 (2006)

- Aalbers, T.H.L., see Kollaard, R.P. 78, 223
Aaltomaa, S., see Guedea, F. 80, 57
Aarup, L.R., see Korreman, S.S. 80, 257
Abacıoğlu, U., see Ozyar, E. 81, 39
Abrams, R.A., see Khan, A.J. 81, 163
Ackerly, T., see Leong, T. 78, 254
Aebersold, D.M., see Vetterli, D. 79, 101
Agarwal, J.P., see Chopra, S. 81, 1
Agazaryan, N., see Holzscheiter, M.H. 81, 233
Aguilo, F., see Guedea, F. 80, 57
A'Hern, R., see Nutting, C. 80, 39
Ahn, K., see Choi, Y. 81, 158
Ahnesjö, A., see Nyholm, T. 78, 347
Aird, E.G.A., see Rollo Moore, A. 80, 82
Aitasalo, K., see Lindholm, P. 78, 146
Ajlouni, M., see Jin, J.-Y. 78, 177
Akman, F., see Ozyar, E. 81, 39
Akudugu, J.M., R.S. Bell, C. Catton, A.M. Davis, A.M. Griffin, B. O'Sullivan, J.N. Waldron, P.C. Ferguson, J.S. Wunder, R.P. Hill, Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF- β activity 78, 17
Alba, E., see Medina, J.A. 79, 34
Alber, M., see Baum, C. 78, 27
Alber, M., see Thorwarth, D. 80, 151
Aleman, B., see Girinsky, T. 79, 270
Aletti, P., see Lorchel, F. 80, 327
Alfieri, A., see Nguyen, N.P. 80, 302
Allemann, K., see Wergin, M.C. 79, 239
Al-Qaisieh, B., see Ash, D. 79, 185
Alsner, J., see Lukacova, S. 80, 165
Ammor, A., see Peignaux, K. 81, 176
Anacak, Y., see Ozyar, E. 81, 39
Ang, K., see Mason, K.A. 80, 192
Aquino-Parsons, C., see Durand, R.E. 80, 138
Aquino-Parsons, C., see Nordsmark, M. 80, 123
Aratani, K., see Sakata, K.-i. 79, 179
Arcangeli, G., see Soete, G. 80, 78
Arcangeli, S., see Soete, G. 80, 78
Ardiet, J.-M., see Bruna, A. 79, 75
Arguiri, E., see Machtay, M. 81, 196
Ariga, H., see Mason, K.A. 80, 192
Ariga, H., see Raju, U. 80, 185
Asadpour, B., see Pinkawa, M. 78, 41
Asadpour, B., see Pinkawa, M. 81, 284
Asakura, H., see Mori, S. 80, 341
Ash, D., B. Al-Qaisieh, D. Bottomley, B. Carey, J. Joseph, The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer 79, 185
Ashley, S., see Mendes, R. 78, 322
Ashley, S., see Shahidi, M. 78, 1
Atahan, I.L., see Ozyar, E. 81, 39
Ataman, Ö.U., A. Barrett, T. Filleron, A. Kramar, Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: A study of the REACT working group of ESTRO 78, 95
Atula, T., see Saarilahti, K. 78, 270
Atula, T., see Saarilahti, K. 80, 107
Au, G., see Teo, P.M.L. 79, 27
Au, J.S.K., see Teo, P.M.L. 79, 27
Azumi, A., see Ejima, Y. 78, 6
Baba, M., see Mori, S. 80, 341
Baba, S., see Ishiyama, H. 78, 194
Bachtiary, B., see Potter, R. 79, 80
Badzio, A., see Senkus-Konefka, E. 79, 304
Bagchi, D., see Brooker, S. 79, 45
Baier, K., see Guckenberger, M. 79, 59
Baiotto, B., see Stasi, M. 80, 363
Baker, C.R., R. Clements, A. Gately, G.J. Budgell, A separated primary and scatter model for independent dose calculation of intensity modulated radiotherapy 80, 385
Baker, J.H.E., see Huxham, L.A. 78, 138
Bakke, A., see Muren, L.P. 80, 98
Bal, M., see Kim, Y. 79, 198
Ballo, M.T., see Beddar, A.S. 78, 207
Balm, A., see De Schutter, H. 80, 143
Balm, A.J.M., see van den Broek, G.B. 81, 143
Balu-Maestro, C., see Courdi, A. 79, 156
Balyckyi, J., see O'Doherty, Ú.M. 79, 335
Bamberg, M., see Goldner, G. 78, 36
Bamberg, M., see Hehr, T. 80, 33
Banáth, J.P., see Klovov, D. 80, 223
Barbé, B., see De Schutter, H. 80, 143
Barillot, I., see Pötter, R. 78, 67
Barillot, I., see Peignaux, K. 81, 176
Baron, M.-H., see Boehmer, D. 79, 259
Baroni, G., see Spadea, M.F. 79, 170
Barrett, A., see Ataman, Ö.U. 78, 95
Bartelink, H., see Vink, S.R. 80, 207
Bartsch, R., S. Fromm, M. Rudas, C. Wenzel, S. Harbauer, K. Roessler, K. Kitz, G.G. Steger, H.-D. Weitmann, R. Poetter, C.C. Zielinski, K. Dieckmann, Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer – A retrospective analysis 80, 313
Bassler, N., see Holzscheiter, M.H. 81, 233
Battista Ivaldi, G., see Jereczek-Fossa, B.A. 81, 294
Baudefet, C., see Jordan, B.F. 81, 112
Baum, C., M. Alber, M. Birkner, F. Nüsslin, Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities 78, 27
Baum, U., see Brunner, T.B. 81, 190
Bauman, G., E. Wong, K. Trenka, D. Scott, A simple technique for craniospinal radiotherapy in the supine position 80, 394
Bauman, G., see Cozzi, L. 80, 268
Bauman, G., see Rodrigues, G. 80, 374
Bauman, G., see Yartsev, S. 78, 169
Baumann, K., see Burmeister, B.H. 81, 136
Baumann, M., see Eke, I. 80, 178
Baumann, M., see Hölscher, T. 78, 123
Baumann, M., see Krause, M. 80, 112
Baumann, M., see Quennet, V. 81, 130
Baumann, M., see Yaromina, A. 81, 122
Becker, G., see Goldner, G. 78, 36

- Beddar, A.S., S. Krishnan, T.M. Briere, X. Wang, M.E. Delclos, M.T. Ballo, P. Das, S. Gould, J.L. Horton, C.H. Crane, The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators **78**, 207
- Bedford, J.L., see Mendes, R. **78**, 322
- Begg, A.C., see De Schutter, H. **80**, 143
- Beghein, N., see Jordan, B.F. **81**, 112
- Behrensmeier, F., see Vetterli, D. **79**, 101
- Beijnen, J.H., see Vink, S.R. **80**, 207
- Belka, C., see Handrick, R. **80**, 199
- Bell, R.S., see Akudugu, J.M. **78**, 17
- Ben-Arush, M., see Ozyar, E. **81**, 39
- Benavides, M., see Medina, J.A. **79**, 34
- Benjaafar, N., see Coffey, M. **81**, 324
- Bentzen, S.M., see Geh, J.I. **78**, 236
- Bentzen, S.M., see Hölscher, T. **78**, 123
- Bentzen, S.M., see Honore, H.B. **79**, 115
- Beresford, J.A., see Roos, D.E. **80**, 318
- Bernier, J., J. Overgaard, Bridging gaps in translational radiation oncology **80**, 109
- Berry, M.P., see Gogna, N.K. **81**, 9
- Beurskens, H., see Duisters, C. **79**, 285
- Beyer, G., see Holzscheiter, M.H. **81**, 233
- Bhamidipati, P.V., see Nguyen, N.P. **80**, 302
- Biancia, C.D., Response to the letter to the editor **78**, 110
- Binns, D., see Leong, T. **78**, 254
- Birkner, M., see Baum, C. **78**, 27
- Birtwistle-Peyrottes, I., see Courdi, A. **79**, 156
- Blackmore, E., see Holzscheiter, M.H. **81**, 233
- Bladou, F., see Guedea, F. **80**, 57
- Bloemen-van Gurp, E.J., A.W.H. Minken, B.J. Mijnheer, C.J.G. Dehing-Oberye and P. Lambin Clinical implementation of MOSFET detectors for dosimetry in electron beams **80**, 288
- Blank, L.E.C.M., see Pieters, B.R. **80**, 69
- Boehmer, D., P. Maingon, P. Poortmans, M.-H. Baron, R. Miralbell, V. Remouchamps, C. Scrase, A. Bossi, M. Bolla, Guidelines for primary radiotherapy of patients with prostate cancer **79**, 259
- Boerman, O.C., see Troost, E.G.C. **80**, 157
- Boersma, L., see Bosmans, G. **81**, 73
- Boersma, L., see De Ruyscher, D. **80**, 307
- Bogner, J., see Kontriso, K. **81**, 97
- Bolla, M., see Boehmer, D. **79**, 259
- Bollet, M.A., see Bruna, A. **79**, 75
- Bollet, M.A., see Kirova, Y.M. **79**, 310
- Bolt, R.A., see Vieira, S.C. **80**, 86
- Bond, S.J., see Geh, J.I. **78**, 236
- Bonneville, P., see Llacer, C. **78**, 10
- Bonomi, P.D., see Khan, A.J. **81**, 163
- Borchers, H., see Pinkawa, M. **78**, 41
- Borgmann, K., see Zschenker, O. **80**, 236
- Born, E.J., see Vetterli, D. **79**, 101
- Born, T., see Siebert, F.-A. **79**, 298
- Borowska, I., see Senkus-Konefka, E. **79**, 304
- Børresen-Dale, A.-L., see Helland, Å. **80**, 230
- Borst, J., see Wissink, E.H.J. **80**, 214
- Bosmans, G., J. Buijsen, A. Dekker, M. Velders, L. Boersma, D. De Ruyscher, A. Minken, P. Lambin, An "in silico" clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients **81**, 73
- Bosset, J.-F., Distal rectal cancer: Sphincter-sparing is also a challenge for the radiation oncologist **80**, 1
- Bosset, J.F., see Lorchel, F. **80**, 327
- Bossi, A., see Boehmer, D. **79**, 259
- Bottomley, D., see Ash, D. **79**, 185
- Bouffet, E., see Carret, A.-S. **81**, 33
- Bouzourene, H., see Coucke, P.A. **79**, 52
- Brabandere, M.D., see Pötter, R. **78**, 67
- Brada, M., see Mendes, R. **78**, 322
- Bradley, J.D., A.N. Nofal, I.M. El Naqa, W. Lu, J. Liu, J. Hubenschmidt, D.A. Low, R.E. Drzymala, D. Khullar, Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer **81**, 264
- Bragg, C.M., J. Conway, Dosimetric verification of the anisotropic analytical algorithm for radiotherapy treatment planning **81**, 315
- Bremer, R.-H., see De Ruyscher, D. **80**, 307
- Brenne, E., see Kaasa, S. **79**, 278
- Briere, T.M., see Beddar, A.S. **78**, 207
- Briot, E., see Lang, S. **78**, 185
- Bristow, R.G., see Jones, K. **78**, 91
- Broggi, S., see Fiorino, C. **78**, 276
- Brooker, S., S. Martin, A. Pearson, D. Bagchi, J. Earl, L. Gothard, E. Hall, L. Porter, J. Yarnold, Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration **79**, 45
- Bruland, O., see Kaasa, S. **79**, 278
- Bruna, A., P. Gastelblum, L. Thomas, O. Chapet, M.A. Bollet, J.-M. Ardiet, J.-P. Gerard, D. Peiffert, Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: A retrospective study **79**, 75
- Brunner, T.B., A. Ernst-Stecken, I. Jeske, G.G. Grabenbauer, R. Sauer, L. Distel, Molecular verification of stereotactic radiotherapy in rats using ATMPs1981 immunofluorescence **79**, 109
- Brunner, T.B., U. Baum, G.G. Grabenbauer, R. Sauer, U. Lambrecht, Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning **81**, 190
- Budach, W., see Hehr, T. **80**, 33
- Budgell, G.J., see Baker, C.R. **80**, 385
- Budrukkar, A., see Chopra, S. **81**, 1
- Bues, M., E.J. Holupka, P. Meskell, I.D. Kaplan, Effect of random seed placement error in permanent transperineal prostate seed implant **79**, 70
- Buijsen, J., see Bosmans, G. **81**, 73
- Bujko, K., L. Kepka, W. Michalski, M.P. Nowacki, Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials **80**, 4
- Burger, C., see Davis, J.B. **80**, 43
- Burman, C., see Chan, M.F. **79**, 218
- Burmeister, B.H., B.M. Smithers, E. Burmeister, K. Baumann, S. Davis, H. Krawitz, C. Johnson, N. Spry, A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma—Trans Tasman Radiation Oncology Group (TROG) Study 96.06 **81**, 136
- Burmeister, B.H., see Roos, D.E. **80**, 318
- Burmeister, E., see Burmeister, B.H. **81**, 136
- Busch, R., see Geinitz, H. **79**, 341
- Bussiere, M.R., see Weber, D.C. **81**, 243
- Bussink, J., see Troost, E.G.C. **80**, 157
- Buter, J., see Vergeer, M.R. **79**, 39
- Buus, S., C. Grau, O.L. Munk, A. Rodell, K. Jensen, K. Mouridsen, S. Keiding, Individual radiation response of parotid glands investigated by dynamic ¹¹C-methionine PET **78**, 262
- Byrne, J.P., see Klovov, D. **80**, 223
- Calandrino, R., see Fiorino, C. **78**, 276
- Call, T.G., see Miller, R.C. **80**, 323
- Caloglu, M., see Ozyar, E. **81**, 39
- Cambria, R., see Cattani, F. **79**, 65
- Cambria, R., see Jereczek-Fossa, B.A. **81**, 294
- Campana, F., see Kirova, Y.M. **79**, 310

- Caneva, S., M.F. Tsiakalos, S. Stathakis, S. Zefkili, A. Mazal, J.-C. Rosenwald, Application of the quality index methodology for dosimetric verification of build-up effect beyond air-tissue interface in treatment planning system algorithms **79**, 208
- Cao, H., see Le, Q.-T. **78**, 230
- Carey, B., see Ash, D. **79**, 185
- Carl, J., B. Lund, E. Hoejkjaer Larsen, J. Nielsen, Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy **78**, 199
- Carret, A.-S., U. Tabori, B. Crooks, J. Hukin, I. Odame, D.L. Johnston, D.L. Keene, C. Freeman, E. Bouffet, Outcome of secondary high-grade glioma in children previously treated for a malignant condition: A study of the Canadian Pediatric Brain Tumour Consortium **81**, 33
- Cattani, F., A. Vavassori, A. Polo, E. Rondi, R. Cambria, R. Orecchia, G. Tosi, Radiation exposure after permanent prostate brachytherapy **79**, 65
- Cattani, F., see Jereczek-Fossa, B.A. **81**, 294
- Catton, C., see Akudugu, J.M. **78**, 17
- Cavanaugh, S.X., see Fuller, C.D. **81**, 65
- Cengel, K., see Machtay, M. **81**, 196
- Cha, W.-W., see Lu, J.-C. **79**, 21
- Chan, A.T.C., see Teo, P.M.L. **79**, 27
- Chan, A.W., see Weber, D.C. **81**, 243
- Chan, M.F., C.S. Chui, Y. Song, C. Burman, E. Yorke, C. Della-Biancia, K.E. Rosenzweig, K. Schupak, A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons **79**, 218
- Chan, W., see Nguyen, N.P. **80**, 302
- Chapellier, C., see Courdi, A. **79**, 156
- Chapet, O., M. Khodri, P. Jalade, D. N'guyen, I. Flandin, A. D'hombres, P. Romestaing, F. Mornex, Potential benefits of using non coplanar field and intensity modulated radiation therapy to preserve the heart in irradiation of lung tumors in the middle and lower lobes **80**, 333
- Chapet, O., see Bruna, A. **79**, 75
- Chen, J., see Rodrigues, G. **80**, 374
- Chen, J., see Yartsev, S. **78**, 169
- Chen, Q., see Jin, J.-Y. **78**, 177
- Chen, W.-Z., see Lu, J.-C. **79**, 21
- Chen, Y.-J., see Pezner, R.D. **81**, 81
- Cheung, P.C.F., see Hoisak, J.D.P. **78**, 339
- Chevreau, C., see Ll  cer, C. **78**, 10
- Chien, C.-R., C.-H. Yang, C.D. Biancia, Thoracic radiotherapy for stage IV non-small cell lung cancer **78**, 110
- Childs, P., see O'Doherty,   .M. **79**, 335
- Cho, B.C.J., T. Craig, More optimal dose distributions for moving lung tumours: A planning study **79**, 122
- Cho, H., see Choi, Y. **81**, 158
- Choi, Y., J.-K. Kim, H.-S. Lee, W.-J. Hur, Y.-S. Hong, S. Park, K. Ahn, H. Cho, Influence of intravenous contrast agent on dose calculations of intensity modulated radiation therapy plans for head and neck cancer **81**, 158
- Chopra, S., T. Gupta, J.P. Agarwal, A. Budrukkar, S. Ghosh-Laskar, K. Dinshaw, Re-irradiation in the management of isolated neck recurrences: Current status and recommendations **81**, 1
- Chou, S.-C., see Nordsmark, M. **80**, 123
- Christensen, J.J., see Tanderup, K. **79**, 87
- Christofidou-Solomidou, M., see Machtay, M. **81**, 196
- Chua, D., see Teo, P.M.L. **79**, 27
- Chui, C.S., see Chan, M.F. **79**, 218
- Ciernik, I.F., see Davis, J.B. **80**, 43
- Ciernik, I.F., see Kr  yenbuehl, J. **81**, 151
- Ciocca, M., V. Piazzi, R. Lazzari, A. Vavassori, A. Luini, P. Veronesi, V. Galimberti, M. Intra, A. Guido, G. Tosi, U. Veronesi, R. Orecchia, Real-time in vivo dosimetry using micro-MOSFET detectors during intraoperative electron beam radiation therapy in early-stage breast cancer **78**, 213
- Classen, J., see Hehr, T. **80**, 33
- Clements, R., see Baker, C.R. **80**, 385
- Clivio, A., see Cozzi, L. **80**, 268
- Coad, T., see Yartsev, S. **78**, 169
- Cobo, M., see Medina, J.A. **79**, 34
- Coebergh, J.W.W., see Vulto, A. **78**, 131
- Coffey, J., see Mangar, S.A. **80**, 355
- Coffey, M., P. Engel-Hills, M. El-Gantiry, N. Benjaafar, K. Wilkinson, B. Vikram, A core curriculum for RTTs (radiation therapists/radiotherapy radiographers) designed for developing countries under the auspices of the international atomic energy agency (IAEA) **81**, 324
- Coghe, M., see Paelinck, L. **81**, 250
- Collan, J., see Saarilahti, K. **78**, 270
- Collan, J., see Saarilahti, K. **80**, 107
- Condron, S., see Leong, T. **78**, 254
- Contreras, J., see Medina, J.A. **79**, 34
- Conway, J., see Bragg, C.M. **81**, 315
- Cooke, D.L., see Ekaette, E.U. **80**, 282
- Coppens, L., see Nickers, P. **79**, 329
- Cora, S., see Cozzi, L. **80**, 268
- Corallo, A., A. Vavassori, D. Zerini, G.B. Ivaldi, O. DeCobelli, R. Orecchia, B.A. Jereczek-Fossa, F. Cattani, A. D'Onofrio, R. Cambria, A. Kowalczyk, Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs) **81**, 294
- Corallo, A., see Jereczek-Fossa, B.A. **81**, 294
- Cordes, N., see Eke, I. **80**, 178
- Cormack, R., see Court, L.E. **81**, 184
- Corstens, F.H.M., see de Geus-Oei, L.-F. **80**, 51
- Cosset, J.-M., see Cousins, C. **80**, 395
- Coucke, P.A., M. Notter, B. Stamm, M. Matter, F. Fasolini, R. Schlumpf, O. Matzinger, H. Bouzourene, Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial **79**, 52
- Courdi, A., C. Ortholan, J.-M. Hannoun-L  vi, J.-M. Ferrero, R. Largillier, C. Balu-Maestro, C. Chapellier, F. Ettore, I. Birtwisle-Peyrottes, Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients **79**, 156
- Court, L.E., A.V. D'Amico, D. Kadam, R. Cormack, Motion and shape change when using an endorectal balloon during prostate radiation therapy **81**, 184
- Cousins, C., J.-M. Cosset, Letter to the editor **80**, 395
- Cozzi, L., A. Clivio, G. Bauman, S. Cora, G. Nicolini, R. Pellegrini, E. Vanetti, S. Yartsev, A. Fogliata, Comparison of advanced irradiation techniques with photons for benign intracranial tumours **80**, 268
- Cr  hange, G., see Peignaux, K. **81**, 176
- Craig, T., see Cho, B.C.J. **79**, 122
- Crane, C.H., see Beddar, A.S. **78**, 207
- Crokart, N., see Jordan, B.F. **81**, 112
- Crooks, B., see Carret, A.-S. **81**, 33
- Cunningham, D., see Shahidi, M. **78**, 1
- Cygler, J.E., A. Saoudi, G. Perry, C. Morash, C. E., Feasibility study of using MOSFET detectors for in vivo dosimetry during permanent low-dose-rate prostate implants **80**, 296
- Dahan, M., see Guldner, L. **81**, 47
- Dahl, O., see Muren, L.P. **80**, 98
- Daisne, J.-F., see Geets, X. **78**, 291
- Daly-Schweitzer, N., see Ll  cer, C. **78**, 10
- Dam, J.V., see Rou  , A. **78**, 78

- Damen, E.M.F., see van Asselen, B. 79, 162
D'Amico, A.V., see Court, L.E. 81, 184
Das, B.P., see Suhag, V. 78, 84
Das, P., see Beddar, A.S. 78, 207
Davidson, S.E., see Nordsmark, M. 80, 123
Davies, M., see O'Doherty, Ú.M. 79, 335
Davis, A.M., see Akudugu, J.M. 78, 17
Davis, J.B., B. Reiner, M. Huser, C. Burger, G. Székely, I.F. Ciernik, Assessment of ^{18}F PET signals for automatic target volume definition in radiotherapy treatment planning 80, 43
Davis, J.B., see Krayenbuehl, J. 81, 151
Davis, S., see Burmeister, B.H. 81, 136
de Boer, H.C.J., see van Zijtvelde, M. 81, 168
De Brabandere, M., C. Kirisits, R. Peeters, K. Haustermans, F. Van den Heuvel, Accuracy of seed reconstruction in prostate post-planning studied with a CT- and MRI-compatible phantom 79, 190
De Brabandere, M., see Lang, S. 78, 185
De Gersem, W., see Paelinck, L. 81, 250
De Gersem, W., see Vanderstraeten, B. 79, 249
de Geus-Oei, L.-F., J.H.A.M. Kaanders, L.A.M. Pop, F.H.M. Corstens, W.J.G. Oyen, Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer 80, 51
de Kruijff, W.J.M., see Kolkman-Deurloo, I.K. 78, 53
de Leval, J., see Nickers, P. 79, 329
De Martin, E., see Fiorino, C. 78, 276
De Meerleer, G., see Soete, G. 80, 78
De Neve, W., see Paelinck, L. 81, 250
De Neve, W., see Soete, G. 80, 78
De Neve, W., see Vanderstraeten, B. 79, 249
de Pasos, A.S., see Medina, J.A. 79, 34
de Reijke, T.M., see Pieters, B.R. 80, 69
De Ruyscher, D., R.-H. Bremer, F. Koppe, S. Wanders, E. van Haren, M. Hochstenbag, W. Geeraedts, C. Pitz, J. Simons, G. ten Velde, J. Dohmen, G. Snoep, L. Boersma, T. Verschuere, A. van Baardwijk, C. Dehing, M. Pijls, A. Minken, P. Lambin, Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial 80, 307
De Ruyscher, D., see Bosmans, G. 81, 73
De Ruyscher, D., see Duisters, C. 79, 285
De Schutter, H., B. Barbé, M. Spaepen, A.C. Begg, A. Balm, V. Gregoire, K. Haustermans, P. Mahy, V. Vander Poorten, S. Nuyts, Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1 80, 143
De Smedt, B., see Paelinck, L. 81, 250
de Vathaire, F., see Guldner, L. 81, 47
de Vroome, H., see Kollaard, R.P. 78, 223
De Wagter, C., see Paelinck, L. 81, 250
de Wilde, P.C.M., see Jonathan, R.A. 79, 288
Dearnaley, D.P., see O'Doherty, Ú.M. 79, 335
Dearnaley, D.P., see Mangar, S.A. 80, 355
Dearnaley, D.P., see Rollo Moore, A. 80, 82
Debucquoy, A., L. Goethals, K. Geboes, S. Roels, W.H. Mc Bride, K. Haustermans, Molecular responses of rectal cancer to preoperative chemoradiation 80, 172
DeCobelli, O., see Jereczek-Fossa, B.A. 81, 294
Deguchi, T., see Tanaka, O. 81, 303
Dehing, C., see De Ruyscher, D. 80, 307
Dehing-Oberye, C.J.G., see Bloemen-van Gurp, E.J. 80, 288
Dekker, A., see Bosmans, G. 81, 73
DeLaney, T.F., see Weber, D.C. 81, 243
Delannes, M., see Llácer, C. 78, 10
Delclos, M.E., see Beddar, A.S. 78, 207
Della-Biancia, C., see Chan, M.F. 79, 218
Dell'Oca, I., see Fiorino, C. 78, 276
DeMarco, J.J., see Holzscheiter, M.H. 81, 233
Demirel, C., see Pinkawa, M. 81, 284
Demizu, Y., see Ejima, Y. 78, 6
Dendale, R., see Kirova, Y.M. 79, 310
Deneufbourg, J.M., see Nickers, P. 78, 47
Deneufbourg, J.-M., see Nickers, P. 79, 329
Desrosiers, P., see Spiridovich, S. 78, 159
D'hombres, A., see Chapet, O. 80, 333
Diallo, I., see Guldner, L. 81, 47
Dieckmann, K., see Bartsch, R. 80, 313
Dieckmann, K., see Kontriso, K. 81, 97
Dikomey, E., see Zschenker, O. 80, 236
Dimopoulos, J., see Kirisits, C. 81, 269
Dimopoulos, J., see Lang, S. 78, 185
Dimopoulos, J., see Pötter, R. 78, 67
Dimopoulos, J., see Potter, R. 79, 80
Dinshaw, K., see Chopra, S. 81, 1
Dirix, P., K. Haustermans, S. Junius, R. Withers, R. Oyen, H. Van Poppel, The role of whole pelvic radiotherapy in locally advanced prostate cancer 79, 1
Dirkx, M.L.P., see van Zijtvelde, M. 81, 168
Dirkx, M.L.P., see Vieira, S.C. 80, 86
Distel, L., see Brunner, T.B. 79, 109
Distel, L.V.R., S. Neubauer, U. Keller, C.N. Sprung, R. Sauer, G.G. Grabenbauer, Individual differences in chromosomal aberrations after *in vitro* irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients 81, 257
Dohmen, J., see De Ruyscher, D. 80, 307
D'Onofrio, A., see Jereczek-Fossa, B.A. 81, 294
Doornaert, P., see Langendijk, J.A. 78, 306
Doornaert, P., see Vergeer, M.R. 79, 39
Dörr, W., see Jaal, J. 80, 250
Doser, M., see Holzscheiter, M.H. 81, 233
Dries, W.J.F., see Kollaard, R.P. 78, 223
Drummond, K.J., see Roos, D.E. 80, 318
Drzymala, R.E., see Bradley, J.D. 81, 264
D'Souza, D., see Rodrigues, G. 80, 374
Dubbelman, R., see Vink, S.R. 80, 207
Duchesne, G.M., see Gogna, N.K. 81, 9
Duisters, C., H. Beurskens, S. Nijsten, M. Starmans, S. Wanders, T. Verschuere, P. Lambin, A. Minken, D. De Ruyscher, Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer 79, 285
Dumas, I., see Lang, S. 78, 185
Dumas, I., see Pötter, R. 78, 67
Dumas, J.L., see Lorchel, F. 80, 327
Duncan, G., see Pickles, T. 78, 107
Dunscombe, P.B., see Ekaette, E.U. 80, 282
Duprez, T., see Geets, X. 78, 291
Durand, R.E., C. Aquino-Parsons, The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy 80, 138
Durand, R.E., see Holzscheiter, M.H. 81, 233
Duthoy, W., see Vanderstraeten, B. 79, 249
E., C., see Cygler, J.E. 80, 296
Earl, J., see Brooker, S. 79, 45
Eble, M.J., see Pinkawa, M. 78, 41
Eble, M.J., see Pinkawa, M. 81, 284
Eibl, H., see Handrick, R. 80, 199
Eicheler, W., see Yaromina, A. 81, 122
Eisbruch, A., see Gregoire, V. 79, 15
Ejima, Y., R. Sasaki, Y. Okamoto, T. Maruta, A. Azumi, Y. Hayashi, Y. Demizu, Y. Ota, T. Soejima, K. Sugimura, Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy 78, 6

- Ekaette, E.U., R.C. Lee, D.L. Cooke, K.-L. Kelly, P.B. Dunscombe, Risk analysis in radiation treatment: Application of a new taxonomic structure **80**, 282
- Eke, I., V. Sandfort, A. Mischkus, M. Baumann, N. Cordes, Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin **80**, 178
- El Naqa, I.M., see Bradley, J.D. **81**, 264
- El-Gantiry, M., see Coffey, M. **81**, 324
- Elomaa, L., see Lindholm, P. **78**, 146
- Endo, M., see Mori, S. **80**, 341
- Engel, J., see Vink, S.R. **80**, 207
- Engel-Hills, P., see Coffey, M. **81**, 324
- Erber, C., see Geinitz, H. **79**, 341
- Erickson, B., see Pötter, R. **78**, 67
- Eriksen, J.G., M.R. Horsman, Tumour hypoxia - A characteristic feature with a complex molecular background **81**, 119
- Ernst-Stecken, A., O. Ganslandt, U. Lambrecht, R. Sauer, G. Grabenbauer, Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity **81**, 18
- Ernst-Stecken, A., see Brunner, T.B. **79**, 109
- Eschmann, S.-M., see Thorwarth, D. **80**, 151
- Ettore, F., see Courdi, A. **79**, 156
- Evans, A.W., see Jones, K. **78**, 91
- Evans, W.K., see Ung, Y.C. **80**, 13
- Everitt, C., see Leong, T. **78**, 254
- Falkmer, U., see Kaasa, S. **79**, 278
- Falkson, C., see Ung, Y.C. **80**, 13
- Faltin, H., see Handrick, R. **80**, 199
- Fasolini, F., see Coucke, P.A. **79**, 52
- Fayers, P., see Kaasa, S. **79**, 278
- Fazio, F., see Fiorino, C. **78**, 276
- Feldmann, H., see Goldner, G. **78**, 36
- Ferguson, P.C., see Akudugu, J.M. **78**, 17
- Ferreira, I.H., see Roué, A. **78**, 78
- Ferrero, J.-M., see Courdi, A. **79**, 156
- Filleron, T., see Ataman, Ö.U. **78**, 95
- Fiorino, C., I. Dell' Oca, A. Pierelli, S. Broggi, E. De Martin, N. Di Muzio, B. Longobardi, F. Fazio, R. Calandrino, Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy **78**, 276
- Fiorino, C., see Stasi, M. **80**, 363
- Fischedick, K., see Pinkawa, M. **78**, 41
- Fitzek, M.M., see Weber, D.C. **81**, 243
- Fitzgibbon, E., see Samant, R.S. **78**, 101
- Flandin, I., see Chapet, O. **80**, 333
- Flentje, M., see Guckenberger, M. **79**, 59
- Flentje, M., see Said, H. **78**, 230
- Fodor, J., see Major, T. **79**, 321
- Fogliata, A., see Cozzi, L. **80**, 268
- Fonteyne, V., see Soete, G. **80**, 78
- Forman, J.D., see Van den Heuvel, F. **79**, 94
- Fournier-Bidoz, N., see Kirova, Y.M. **79**, 310
- Fourquet, A., see Kirova, Y.M. **79**, 310
- Frank, C., see Nguyen, N.P. **80**, 302
- Freeman, C., see Carret, A.-S. **81**, 33
- Freeman, C.R., see Parker, W.A. **78**, 217
- Frigerio, G., see Monti, A.F. **81**, 88
- Fromm, S., see Bartsch, R. **80**, 313
- Frøyland, C., see Helland, Å. **80**, 230
- Fugazzi, J., see Van den Heuvel, F. **79**, 94
- Fujita, T., see Ishiyama, H. **78**, 194
- Fuks, Z., see Ling, C.C. **78**, 119
- Fuller, C.D., C.R. Thomas Jr., A. Wong, S.X. Cavanaugh, B.J. Salter, T.S. Herman, M. Fuss, Image-guided intensity-modulated radiation therapy for gallbladder carcinoma **81**, 65
- Fuss, M., see Fuller, C.D. **81**, 65
- Fuwa, N., see Sakata, K.-i. **79**, 179
- Fyles, A., M. Milosevic, M. Pintilie, A. Syed, W. Levin, L. Manchul, R.P. Hill, Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer **80**, 132
- Gabriele, P., see Stasi, M. **80**, 363
- Gagel, B., see Pinkawa, M. **78**, 41
- Gagel, B., see Pinkawa, M. **81**, 284
- Galimberti, V., see Ciocca, M. **78**, 213
- Gallez, B., see Jordan, B.F. **81**, 112
- Ganslandt, O., see Ernst-Stecken, A. **81**, 18
- Ganswindt, U., see Hehr, T. **80**, 33
- Garibaldi, C., see Spadea, M.F. **79**, 170
- Gastelblum, P., see Bruna, A. **79**, 75
- Gately, A., see Baker, C.R. **80**, 385
- Geboes, K., see Debucquoy, A. **80**, 172
- Gebski, V., see Nordmark, M. **80**, 123
- Geeraedts, W., see De Ruyscher, D. **80**, 307
- Geets, X., J.-F. Daisne, M. Tomsej, T. Duprez, M. Lonnew, V. Grégoire, Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies **78**, 291
- Geh, J.I., S.J. Bond, S.M. Bentzen, R. Glynne-Jones, Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response **78**, 236
- Geinitz, H., F.B. Zimmermann, R. Thamm, C. Erber, T. Muller, M. Keller, R. Busch, M. Molls, Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer **79**, 341
- Geinitz, H., see Goldner, G. **78**, 36
- Georg, D., see Georg, P. **80**, 19
- Georg, D., see Kirisits, C. **81**, 269
- Georg, D., see Kontriso, K. **81**, 97
- Georg, D., see Lang, S. **78**, 185
- Georg, P., D. Georg, M. Hillbrand, C. Kirisits, R. Pötter, Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies **80**, 19
- Gérard, J.-P., see Bruna, A. **79**, 75
- Ghalibafian, M., see Girinsky, T. **79**, 270
- Ghoshal, S., see Saibishkumar, E.P. **79**, 142
- Ghosh-Laskar, S., see Chopra, S. **81**, 1
- Giacca, A., see Le, Q.-T. **78**, 230
- Gianolini, S., see Mangar, S.A. **80**, 355
- Gifford, K.A., see Kendall, R.L. **81**, 206
- Girinsky, T., R. van der Maazen, L. Specht, B. Aleman, P. Poortmans, Y. Lievens, P. Meijnders, M. Ghalibafian, J. Meerwaldt, E. Noordijk, Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines **79**, 270
- Gjertsen, T., see Helland, Å. **80**, 230
- Glocker, S., see Goldner, G. **78**, 36
- Glogar, D., see Syeda, B. **78**, 60
- Glynne-Jones, R., see Geh, J.I. **78**, 236
- Goethals, L., see Debucquoy, A. **80**, 172
- Gogna, N.K., J.H.L. Matthews, S.L. Turner, H. Mameghan, G.M. Duchesne, N. Spry, M.P. Berry, J. Keller, L. Tripcony, Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group **81**, 9
- Goldberg, S.I., see Weber, D.C. **81**, 243
- Goldner, G., F. Zimmermann, H. Feldmann, S. Glocker, N. Wachter-Gerstner, H. Geinitz, G. Becker, R. Pötzi, A. Wambersie, M. Bamberg, M. Molls, S. Wachter, R. Pötter, 3-D conformal radiotherapy of localized prostate cancer: A subgroup analysis of rec-

- toscopic findings prior to radiotherapy and acute/late rectal side effects **78**, 36
- Gothard, L., see Brooker, S. **79**, 45
- Gottsauer-Wolf, M., see Syeda, B. **78**, 60
- Gould, S., see Beddar, A.S. **78**, 207
- Grabenbauer, G., see Ernst-Stecken, A. **81**, 18
- Grabenbauer, G.G., see Brunner, T.B. **79**, 109
- Grabenbauer, G.G., see Brunner, T.B. **81**, 190
- Grabenbauer, G.G., see Distel, L.V.R. **81**, 257
- Graham, I.D., see Samant, R.S. **78**, 101
- Graham, P., see Pickles, T. **78**, 107
- Granfeldt, J., see Tanderup, K. **79**, 87
- Grau, C., see Buus, S. **78**, 262
- Grau, C., see Jensen, K. **78**, 298
- Grau, C., see Nielsen, H.M. **79**, 147
- Grau, C., see Tanderup, K. **79**, 245
- Grau, C., see Tanderup, K. **81**, 105
- Gravis, G., see Guedea, F. **80**, 57
- Grégoire, V., A. Eisbruch, M. Hamoir, P. Levendag, Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck **79**, 15
- Grégoire, V., see Geets, X. **78**, 291
- Grégoire, V., see Jordan, B.F. **81**, 112
- Grénman, R., see Lindholm, P. **78**, 146
- Gregoire, V., see De Schutter, H. **80**, 143
- Greiner, R.H., see Vetterli, D. **79**, 101
- Griffin, A.M., see Akudugu, J.M. **78**, 17
- Grigorov, G., see Rodrigues, G. **80**, 374
- Grosu, A.-L., see Nestle, U. **81**, 209
- Guazzoni, G., see Guedea, F. **80**, 57
- Guckenberger, M., F. Pohl, K. Baier, J. Meyer, D. Vordermark, M. Flentje, Adverse effect of a distended rectum in intensity-modulated radiotherapy (IMRT) treatment planning of prostate cancer **79**, 59
- Guido, A., see Ciocca, M. **78**, 213
- Guldner, L., N. Haddy, F. Pein, I. Diallo, A. Shamsaldin, M. Dahan, J. Leblond, P. Merlet, E. Villain, D. Sidi, O. Sakiroglu, O. Hartmann, D. Leftakopoulos, F. de Vathaire, Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer **81**, 47
- Gupta, T., see Chopra, S. **81**, 1
- Haase, M., see Yaromina, A. **81**, 122
- Haddy, N., see Guldner, L. **81**, 47
- Haie-Meder, C., see Lang, S. **78**, 185
- Haie-Meder, C., see Pötter, R. **78**, 67
- Hall, E., see Brooker, S. **79**, 45
- Hall, E.J., Antiprotons for radiotherapy? **81**, 231
- Halvorsen, O.J., see Muren, L.P. **80**, 98
- Hamoir, M., see Gregoire, V. **79**, 15
- Han, C., see Pezner, R.D. **81**, 81
- Handrick, R., A. Rübel, H. Faltin, H. Eibl, C. Belka, V. Jendrosseck, Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling **80**, 199
- Hannoun-Levi, J.-M., see Courdi, A. **79**, 156
- Hansen, O., see Nielsen, M. **78**, 165
- Harbauer, S., see Bartsch, R. **80**, 313
- Hareyama, M., see Sakata, K.-i. **79**, 179
- Haring, S., see Siebert, F.-A. **79**, 298
- Harrington, K., see Nutting, C. **80**, 39
- Härtley, O., see Holzscheiter, M.H. **81**, 233
- Hartmann, O., see Guldner, L. **81**, 47
- Hashiba, H., see Suzuki, M. **78**, 283
- Hauptmann, M., see van den Broek, G.B. **81**, 143
- Haustermans, K., see De Brabandere, M. **79**, 190
- Haustermans, K., see De Schutter, H. **80**, 143
- Haustermans, K., see Debucquoy, A. **80**, 172
- Haustermans, K., see Dirix, P. **79**, 1
- Havsteen, H., see Nordsmark, M. **80**, 123
- Hayakawa, K., see Ishiyama, H. **78**, 194
- Hayashi, S., see Tanaka, O. **81**, 303
- Hayashi, Y., see Ejima, Y. **78**, 6
- Haynes, A.E., see Ung, Y.C. **80**, 13
- Hehr, T., J. Classen, S. Welz, U. Ganswindt, H. Scheithauer, A. Koitschev, M. Bamberg, W. Budach, Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study **80**, 33
- Heijmen, B.J.M., see van Zijteld, M. **81**, 168
- Heijmen, B.J.M., see Vieira, S.C. **80**, 86
- Helland, Å., H. Johnsen, C. Frøyland, H.B.K. Landmark, A.B. Sætersdal, M.M. Holmen, T. Gjertsen, J.M. Nesland, W. Ottestad, S.S. Jeffrey, L.O. Ottestad, O.K. Rodningen, G. Sherlock, A.-L. Børresen-Dale, Radiation-induced effects on gene expression: An in vivo study on breast cancer **80**, 230
- Hellebust, T.P., see Tanderup, K. **81**, 105
- Henderson, A., see Guedea, F. **80**, 57
- Henk, J.M., see Nutting, C. **80**, 39
- Henrys, A., see Mendes, R. **78**, 322
- Herman, T.S., see Fuller, C.D. **81**, 65
- Hicks, R.J., see Leong, T. **78**, 254
- Hill, R.P., see Akudugu, J.M. **78**, 17
- Hill, R.P., see Fyles, A. **80**, 132
- Hill, R.P., see Langan, A.R. **79**, 231
- Hillbrand, M., see Georg, P. **80**, 19
- Hillebrand, M.J.X., see Vink, S.R. **80**, 207
- Hochstenbag, M., see De Ruyscher, D. **80**, 307
- Hoevels, M., see Treuer, H. **81**, 25
- Hoisak, J.D.P., K.E. Sixel, R. Tirona, P.C.F. Cheung, J.-P. Pignol, Prediction of lung tumour position based on spirometry and on abdominal displacement: Accuracy and reproducibility **78**, 339
- Holmberg, M., see Kaasa, S. **79**, 278
- Holmen, M.M., see Helland, Å. **80**, 230
- Hölscher, T., S.M. Bentzen, M. Baumann, Influence of connective tissue diseases on the expression of radiation side effects: A systematic review **78**, 123
- Holupka, E.J., see Bues, M. **79**, 70
- Holy, R., see Pinkawa, M. **81**, 284
- Holzner, F., see Thorwarth, D. **80**, 151
- Holzscheiter, M.H., N. Bassler, N. Agazaryan, G. Beyer, E. Blackmore, J.J. DeMarco, M. Doser, R.E. Durand, O. Hartley, K.S. Iwamoto, H.V. Knudsen, R. Landua, C. Maggiore, W.H. McBride, S.P. Møller, J. Petersen, L.D. Skarsgard, J.B. Smathers, T.D. Solberg, U.I. Uggerhøj, S. Vranjes, H.R. Withers, M. Wong, B.G. Wouters, The biological effectiveness of antiproton irradiation **81**, 233
- Hong, Y.-S., see Choi, Y. **81**, 158
- Honoré, H.B., see Tanderup, K. **81**, 105
- Honore, H.B., S.M. Bentzen, A modelling study of the potential influence of low dose hypersensitivity on radiation treatment planning **79**, 115
- Hooper, S., see O'Doherty, Ú.M. **79**, 335
- Horlock, N., see Nutting, C. **80**, 39
- Horsman, M.R., S. Lukacova, J. Overgaard, J. Alsner, Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models **80**, 165
- Horsman, M.R., see Eriksen, J.G. **81**, 119
- Horsman, M.R., see Lukacova, S. **80**, 165
- Høstmark, J., see Muren, L.P. **80**, 98
- Horton, J.L., see Beddar, A.S. **78**, 207
- Horwich, A., see Shahidi, M. **78**, 1
- Hoshi, H., see Tanaka, O. **81**, 303
- Hubenschmidt, J., see Bradley, J.D. **81**, 264

- Huddart, R.A., see O'Doherty, U.M. 79, 335
- Hugo, G., C. Vargas, J. Liang, L. Kestin, J.W. Wong, D. Yan, Changes in the respiratory pattern during radiotherapy for cancer in the lung 78, 326
- Hui, A., see Carret, A.-S. 81, 33
- Hulshof, M., see Leong, T. 78, 254
- Hukin, J.C.C.M., see Pieters, B.R. 80, 69
- Hunsche, S., see Treuer, H. 81, 25
- Hunter, N., see Mason, K.A. 80, 192
- Hunter, R., see Nordsmark, M. 80, 123
- Hur, W.-J., see Choi, Y. 81, 158
- Hurkmans, C.W., see Meijer, G.J. 80, 378
- Huser, M., see Davis, J.B. 80, 43
- Huxham, L.A., A.H. Kyle, J.H.E. Baker, K.L. McNicol, A.I. Minchinton, Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts 78, 138
- Hysing, L.B., Y. Kvinnsland, H. Lord, L.P. Muren, Planning organ at risk volume margins for organ motion of the intestine 80, 349
- Ikeda, H., see Sakata, K.-i. 79, 179
- Inoue, T., see Yoshioka, Y. 80, 62
- Inteeworn, N., see Wergin, M.C. 79, 239
- Intra, M., see Ciocca, M. 78, 213
- Ishiyama, H., H. Tsuji, T. Kamada, T. Yanagi, J.-E. Mizoe, T. Kanai, S. Morita, M. Wakatsuki, J. Shimazaki, H. Tsujii, Carbon ion radiotherapy for prostate cancer: Results of a prospective phase II study 81, 57
- Ishiyama, H., M. Kitano, T. Satoh, Y. Niibe, M. Uemae, T. Fujita, S. Baba, K. Hayakawa, Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer 78, 194
- Ito, Y., see Sekine, I. 80, 93
- Iwamoto, K.S., see Holzscheiter, M.H. 81, 233
- Jaal, J., W. Dörr, Radiation-induced damage to mouse urothelial barrier 80, 250
- Jakse, G., see Pinkawa, M. 78, 41
- Jalade, P., see Chapet, O. 80, 333
- Jansen, N., see Nickers, P. 78, 47
- Jansen, N., see Nickers, P. 79, 329
- Jassem, J., see Senkus-Konefka, E. 79, 304
- Jeffrey, S.S., see Helland, A. 80, 230
- Jendrosseck, V., see Handrick, R. 80, 199
- Jensen, A.B., see Jensen, K. 78, 298
- Jensen, A.R., see Nielsen, H.M. 79, 147
- Jensen, K., A.B. Jensen, C. Grau, The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires 78, 298
- Jensen, K., see Buus, S. 78, 262
- Jerezek-Fossa, B.A., F. Cattani, A. D'Onofrio, R. Cambria, A. Kowalczyk, A. Corallo, A. Vavassori, D. Zerini, G. Battista Ivaldi, O. DeCobelli, R. Orecchia, Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs) 81, 294
- Jeske, I., see Brunner, T.B. 79, 109
- Jha, N., see Saibishkumar, E.P. 80, 106
- Jim Warrington, A.P., see Rollo Moore, A. 80, 82
- Jin, J.-Y., M. Ajlouni, Q. Chen, F.-F. Yin, B. Movsas, A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy 78, 177
- Joensuu, H., see Saarilahti, K. 78, 270
- Joensuu, H., see Saarilahti, K. 80, 107
- Johnsen, H., see Helland, A. 80, 230
- Johnson, C., see Burmeister, B.H. 81, 136
- Johnston, D.L., see Carret, A.-S. 81, 33
- Jonathan, R.A., K.I.E.M. Wijffels, W. Peeters, P.C.M. de Wilde, H.A.M. Marres, M.A.W. Merks, E. Oosterwijk, A.J. van der Kogel, J.H.A.M. Kaanders, The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON 79, 288
- Jones, K., A.W. Evans, R.G. Bristow, W. Levin, Treatment of radiation proctitis with hyperbaric oxygen 78, 91
- Jordan, B.F., N. Beghein, N. Crockart, C. Baudelet, V. Grégoire, B. Gallez, Preclinical safety and antitumor efficacy of insulin combined with irradiation 81, 112
- Joseph, J., see Ash, D. 79, 185
- Josipović, M., see Korreman, S.S. 80, 257
- Juhler-Nøttrup, T., see Korreman, S.S. 80, 257
- Junius, S., see Dirix, P. 79, 1
- Kaanders, J.H.A.M., see de Geus-Oei, L.-F. 80, 51
- Kaanders, J.H.A.M., see Jonathan, R.A. 79, 288
- Kaanders, J.H.A.M., see Troost, E.G.C. 80, 157
- Kaasa, S., E. Brenne, J.-A. Lund, P. Fayers, U. Falkmer, M. Holmberg, M. Lagerlund, O. Bruland, Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy \times 1) versus multiple fractions (3 Gy \times 10) in the treatment of painful bone metastases 79, 278
- Kadam, D., see Court, L.E. 81, 184
- Kälkner, K.M., G. Kubicek, J. Nilsson, M. Lundell, S. Levitt, S. Nilsson, Prostate volume determination: Differential volume measurements comparing CT and TRUS 81, 179
- Kälkner, K.M., J. Nilsson, M. Lundell, S. Levitt, S. Nilsson, Prostate displacement kit: Reducing the radiation dose to the rectum 81, 291
- Kamada, T., see Ishikawa, H. 81, 57
- Kamangari, N., see Shahidi, M. 78, 1
- Kamer, S., see Miller, R.C. 80, 323
- Kanai, T., see Ishikawa, H. 81, 57
- Kanamori, S., see Suzuki, M. 78, 283
- Kandatsu, S., see Mori, S. 80, 341
- Kangasmäki, A., see Saarilahti, K. 78, 270
- Kangasmäki, A., see Saarilahti, K. 80, 107
- Kantor, G., see Llácer, C. 78, 10
- Kaplan, I.D., see Bues, M. 79, 70
- Kapoor, R., see Saibishkumar, E.P. 79, 142
- Kappas, C., see Tsiakalos, M.F. 79, 131
- Karlsson, M., see Nyholm, T. 78, 347
- Karlsson, U., see Nguyen, N.P. 80, 302
- Karunanidhi, G., see Saibishkumar, E.P. 79, 142
- Kaser-Hotz, B., see Wergin, M.C. 79, 239
- Kasperts, N., see Langendijk, J.A. 78, 306
- Kataja, V., J. Palmgren, F. Bladou, N. Salem, G. Gravis, A. Losa, G. Guazzoni, L. Nava, F. Guedea, F. Aguilo, A. Polo, S. Langley, R. Laing, A. Henderson, S. Aaltomaa, Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer 80, 57
- Kataja, V., see Guedea, F. 80, 57
- Katzer, A., see Said, H. 78, 230
- Kaushal, V., see Suhag, V. 78, 84
- Keene, D.L., see Carret, A.-S. 81, 33
- Keiding, S., see Buus, S. 78, 262
- Keller, J., see Gogna, N.K. 81, 9
- Keller, M., see Geinitz, H. 79, 341
- Keller, U., see Distel, L.V.R. 81, 257
- Kelly, K.-L., see Ekaette, E.U. 80, 282
- Kemmerling, L., see Vetterli, D. 79, 101
- Kendall, R.L., K.A. Gifford, S.M. Kirsner, The impact of peak-kilovoltage settings on heterogeneity-corrected photon-beam treatment plans 81, 206

- Kepka, L., see Bujko, K. 80, 4
- Kestin, L., see Hugo, G. 78, 326
- Khan, A.J., P.S. Mehta, T.W. Zusag, P.D. Bonomi, L. Penfield Faber, S. Shott, R.A. Abrams, Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC) 81, 163
- Khan, M.A., see Langan, A.R. 79, 231
- Khodri, M., see Chapet, O. 80, 333, S.A. 80, 355
- Khullar, D., see Bradley, J.D. 81, 264
- Kim, J.-K., see Choi, Y. 81, 158
- Kim, Y., W.A. Tome, M. Bal, T.R. McNutt, L. Spies, The impact of dental metal artifacts on head and neck IMRT dose distributions 79, 198
- Kimmig, B., see Niehoff, P. 79, 316
- Kinniry, P., see Machtay, M. 81, 196
- Kirisits, C., S. Lang, J. Dimopoulos, K. Oechs, D. Georg, R. Pötter, Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer 81, 269
- Kirisits, C., see De Brabandere, M. 79, 190
- Kirisits, C., see Georg, P. 80, 19
- Kirisits, C., see Lang, S. 78, 185
- Kirisits, C., see Pötter, R. 78, 67
- Kirisits, C., see Potter, R. 79, 80
- Kirisits, C., see Syeda, B. 78, 60
- Kirova, Y.M., V. Servois, F. Campana, R. Dendale, M.A. Bollet, F. Laki, N. Fournier-Bidoz, A. Fourquet, CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning 79, 310
- Kirchner, S.M., see Kendall, R.L. 81, 206
- Kitano, M., see Ishiyama, H. 78, 194
- Kitz, K., see Bartsch, R. 80, 313
- Klovov, D., S.M. MacPhail, J.P. Banáth, J.P. Byrne, P.L. Olive, Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays 80, 223
- Klos, B., see Potter, R. 79, 80
- Knocke-Abulesz, T.-H., see Potter, R. 79, 80
- Knudsen, H.V., see Holzscheiter, M.H. 81, 233
- Kocher, M., see Treuer, H. 81, 25
- Kodaira, T., see Sakata, K.-i. 79, 179
- Kodama, T., see Sekine, I. 80, 93
- Koedooder, K., see Pieters, B.R. 80, 69
- Kohno, K., see Mori, S. 80, 341
- Kohno, R., see Mori, S. 80, 341
- Koike, R., see Suzuki, M. 78, 283
- Koitschev, A., see Hehr, T. 80, 33
- Kolkman-Deurloo, I.K., W.J.M. de Kruijf, P.C. Levendag, On-line implant reconstruction in HDR brachytherapy 78, 53
- Kollaard, R.P., W.J.F. Dries, H.J. van Kleffens, T.H.L. Aalbers, H. van der Marel, H.P.A. Marijnissen, M. Piessens, D.R. Schaart, H. de Vroome, Recommendations on detectors and quality control procedures for brachytherapy beta sources 78, 223
- Komatsu, S., see Mori, S. 80, 341
- Konishi, K., see Yoshioka, Y. 80, 62
- Kontrisoova, K., M. Stock, K. Dieckmann, J. Bogner, R. Pötter, D. Georg, Dosimetric comparison of stereotactic body radiotherapy in different respiration conditions: A modeling study 81, 97
- Koong, A., see Le, Q.-T. 78, 230
- Koppe, F., see De Ruyscher, D. 80, 307
- Korremans, S.S., A.N. Pedersen, M. Josipović, L.R. Aarup, T. Juhler-Nøttrup, L. Specht, H. Nyström, Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy 80, 257
- Koto, M., see Raju, U. 80, 185
- Kouri, M., see Saarilahti, K. 78, 270
- Kouri, M., see Saarilahti, K. 80, 107
- Kovacs, G., see Major, T. 79, 321
- Kovacs, G., see Niehoff, P. 79, 316
- Kovacs, G., see Siebert, F.-A. 79, 298
- Kowalczyk, A., see Jereczek-Fossa, B.A. 81, 294
- Kramar, A., see Ataman, Ö.U. 78, 95
- Krause, M., D. Zips, H.D. Thames, J. Kummermehr, M. Baumann, Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy 80, 112
- Krause, M., see Yaromina, A. 81, 122
- Krawitz, H., see Burmeister, B.H. 81, 136
- Krayenbuehl, J., J.B. Davis, I.F. Ciernik, Dynamic intensity-modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer 81, 151
- Kremp, S., see Nestle, U. 81, 209
- Krishnan, S., see Beddar, A.S. 78, 207
- Kron, T., see Rodrigues, G. 80, 374
- Kron, T., see Yartsev, S. 78, 169
- Kubicek, G., see Kalkner, K.M. 81, 179
- Kulmala, J., see Lindholm, P. 78, 146
- Kumar, S., M. Pandey, P. Lal, Letter to the Editor 78, 107
- Kumar, V., see Saibishkumar, E.P. 79, 142
- Kummermehr, J., see Krause, M. 80, 112
- Kunitoh, H., see Sekine, I. 80, 93
- Kvinnslund, Y., see Hysing, L.B. 80, 349
- Kwan, W.H., see Teo, P.M.L. 79, 27
- Kwong, D., see Teo, P.M.L. 79, 27
- Kyle, A.H., see Huxham, L.A. 78, 138
- Lagendijk, J.J.W., see Lagerburg, V. 80, 73
- Lagerburg, V., M.A. Moerland, M. van Vulpen, J.J.W. Lagendijk, A new robotic needle insertion method to minimise attendant prostate motion 80, 73
- Lagerlund, M., see Kaasa, S. 79, 278
- Laine, J., see Lindholm, P. 78, 146
- Laing, R., see Guedea, F. 80, 57
- Laki, F., see Kirova, Y.M. 79, 310
- Lal, P., see Kumar, S. 78, 107
- Laluhova, D., see Wergin, M.C. 79, 239
- Lambin, P., see Bloemen-van Gurp, E.J. 80, 288
- Lambin, P., see Bosmans, G. 81, 73
- Lambin, P., see De Ruyscher, D. 80, 307
- Lambin, P., see Duisters, C. 79, 285
- Lambrecht, U., see Brunner, T.B. 81, 190
- Lambrecht, U., see Ernst-Stecken, A. 81, 18
- Landmark, H.B.K., see Helland, Å. 80, 230
- Landoni, V., see Soete, G. 80, 78
- Landua, R., see Holzscheiter, M.H. 81, 233
- Lang, I., see Syeda, B. 78, 60
- Lang, S., A. Nulens, E. Briot, C. Kirisits, M. De Brabandere, I. Dumas, J. Dimopoulos, P. Petrow, D. Georg, E. Van Limbergen, C. Haie-Meder, R. Pötter, Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations 78, 185
- Lang, S., see Kirisits, C. 81, 269
- Lang, S., see Pötter, R. 78, 67
- Langan, A.R., M.A. Khan, I.W.T. Yeung, J. Van Dyk, R.P. Hill, Partial volume rat lung irradiation: The protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic 79, 231
- Langendijk, J.A., N. Kasperts, C.R. Leemans, P. Doornaert, B.J. Slotman, A phase II study of primary reirradiation in squamous cell carcinoma of head and neck 78, 306
- Langendijk, J.A., see Vergeer, M.R. 79, 39
- Langer, M., see Spiridovich, S. 81, 309
- Langley, S., see Guedea, F. 80, 57
- Largillier, R., see Courdi, A. 79, 156

- Larsen, E. Hoekjaer, see Carl, J. 78, 199
- Laskar, S., see Ozyar, E. 81, 39
- Lau, E.W.F., see Leong, T. 78, 254
- Lau, W.H., see Teo, P.M.L. 79, 27
- Laverman, P., see Troost, E.G.C. 80, 157
- Lavrenkov, K., see Mendes, R. 78, 322
- Law, S.C.K., see Teo, P.M.L. 79, 27
- Lawrence, T.S., see Lin, A. 79, 352
- Lazzari, R., see Ciocca, M. 78, 213
- Le, Q.-T., H. Cao, A. Koong, A. Giaccia, Comment on: Osteopontin as toxic marker 78, 230
- Lebesque, J.V., see van Asselen, B. 79, 162
- Lebidois, J., see Guldner, L. 81, 47
- Lee, A.W.M., see Teo, P.M.L. 79, 27
- Lee, H.-S., see Choi, Y. 81, 158
- Lee, J., see Machtay, M. 81, 196
- Lee, R.C., see Ekaette, E.U. 80, 282
- Leemans, C.R., see Langendijk, J.A. 78, 306
- Leemans, C.R., see Vergeer, M.R. 79, 39
- Leer, J.W.H., see van der Linden, Y.M. 78, 245
- Leftakopoulos, D., see Guldner, L. 81, 47
- Lemanski, C., see Nguyen, N.P. 80, 302
- Leong, T., Everitt, C., Yuen, K., Condrón, S., Hui, A., Ngan, S.Y.K., Pitman, A., Lau, E.W.F., MacManus, M., Binns, D., Ackerly, T., Hicks, R.J., A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer 78, 254
- Lessell, S., see Weber, D.C. 81, 243
- Leung, S.F., see Teo, P.M.L. 79, 27
- Leung, T.W., see Teo, P.M.L. 79, 27
- Levendag, P., see Gregoire, V. 79, 15
- Levendag, P.C., see Kolkman-Deurloo, I.K. 78, 53
- Levin, W., see Fyles, A. 80, 132
- Levin, W., see Jones, K. 78, 91
- Levitt, S., see Kälkner, K.M. 81, 291
- Levitt, S., see Kälkner, K.M. 81, 179
- Lewis, D.G., see Spezi, E. 79, 224
- Li, F., see Lu, J.-C. 79, 21
- Liang, J., see Hugo, G. 78, 326
- Lievens, Y., see Girinsky, T. 79, 270
- Limbergen, E.V., see Pötter, R. 78, 67
- Lin, A., T.S. Lawrence, S. Pergolizzi, E.G. Rossi, An anaphylactoid reaction from amifostine 79, 352
- Lin, A., T.S. Lawrence, S. Pergolizzi, E.G. Rossi, Consideration about axillary nodes and arm position 79, 352
- Lincoln, N., see O'Doherty, Ú.M. 79, 335
- Lindegaard, J.C., see Nordsmark, M. 80, 123
- Lindegaard, J.C., see Tanderup, K. 79, 87
- Lindegaard, J.C., see Tanderup, K. 81, 105
- Lindholm, P., R. Valavaara, K. Aitasalo, J. Kulmala, J. Laine, L. Elomaa, L. Sillanmäki, H. Minn, R. Grénman, Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: A prospective phase II study 78, 146
- Ling, C.C., E. Yorke, Z. Fuks, From IMRT to IGRT: Frontierland or Neverland? 78, 119
- Linthout, N., see Verellen, D. 78, 332
- Liu, A., see Pezner, R.D. 81, 81
- Liu, J., see Bradley, J.D. 81, 264
- Llácer, C., M. Delannes, M. Minsat, E. Stoeckle, L. Votron, P. Martel, P. Bonneville, B. Nguyen Bui, C. Chevreau, G. Kantor, N. Daly-Schveitzer, L. Thomas, Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure 78, 10
- Lock, M., see Rodrigues, G. 80, 374
- Lok, J., see Troost, E.G.C. 80, 157
- Lomax, A., see Steneker, M. 80, 263
- Loncaster, J., see Nordsmark, M. 80, 123
- Longobardi, B., see Fiorino, C. 78, 276
- Lonneux, M., see Geets, X. 78, 291
- Lorchel, F., J.L. Dumas, A. Noël, D. Wolf, J.F. Bosset, P. Aletti, Esophageal cancer: Determination of internal target volume for conformal radiotherapy 80, 327
- Lord, H., see Hysing, L.B. 80, 349
- Losa, A., see Guedea, F. 80, 57
- Louwman, M., see Vulto, A. 78, 131
- Low, D.A., see Bradley, J.D. 81, 264
- Lu, J.-C., B.-Q. Wei, W.-Z. Chen, P.-D. Qian, Y.-Q. Zhang, Q. Wei, W.-W. Cha, F. Li, M. Ni, Staging of nasopharyngeal carcinoma investigated by magnetic resonance imaging 79, 21
- Lu, W., see Bradley, J.D. 81, 264
- Lu, X., see Raju, U. 80, 185
- Luini, A., see Ciocca, M. 78, 213
- Lukacova, S., J. Overgaard, J. Alsner, M. R. Horsman, Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models 80, 165
- Lund, B., see Carl, J. 78, 199
- Lund, J.-A., see Kaasa, S. 79, 278
- Lundell, M., see Kälkner, K.M. 81, 179
- Lundell, M., see Kälkner, K.M. 81, 291
- Luyken, K., see Treuer, H. 81, 25
- Maarouf, M., see Treuer, H. 81, 25
- Machtay, M., A. Scherpereel, J. Santiago, J. Lee, J. McDonough, P. Kinniry, E. Arguiri, V.V. Shuvaev, J. Sun, K. Cengel, C.C. Solomides, M. Christofidou-Solomidou, Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/blb mouse 81, 196
- MacManus, M., see Leong, T. 78, 254
- MacPhail, S.M., see Klovov, D. 80, 223
- Maeda, S., see Tanaka, O. 81, 303
- Maggiore, C., see Holzscheiter, M.H. 81, 233
- Mahy, P., see De Schutter, H. 80, 143
- Maingon, P., see Boehmer, D. 79, 259
- Maingon, P., see Peignaux, K. 81, 176
- Mais, K., see Mangar, S. 78, 152
- Major, T., P. Niehoff, G. Kovacs, J. Fodor, C. Polgar, Dosimetric comparisons between high dose rate interstitial and MammoSite® balloon brachytherapy for breast cancer 79, 321
- Major, T., see Niehoff, P. 79, 316
- Malinverni, G., see Stasi, M. 80, 363
- Mameghan, H., see Gogna, N.K. 81, 9
- Manchul, L., see Fyles, A. 80, 132
- Mangar, S., N. Slevin, K. Mais, A. Sykes, Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: A retrospective review 78, 152
- Mangar, S.A., M.R. Sydes, H.L. Tucker, J. Coffey, S.A. Sohaib, S. Gianolini, S. Webb, V.S. Khoo, D.P. Dearnaley, Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397) 80, 355
- Mansur, D.B., Author's reply 79, 353
- Margaret Bidmead, A., see Rollo Moore, A. 80, 82
- Marijnien, C.A.M., see van der Linden, Y.M. 78, 245
- Marijnissen, H.P.A., see Kollaard, R.P. 78, 223
- Marini, P., see Stasi, M. 80, 363
- Marres, H.A.M., see Jonathan, R.A. 79, 288
- Martel, P., see Llácer, C. 78, 10
- Martin, M., see Ozyar, E. 81, 39
- Martin, S., see Brooker, S. 79, 45
- Maruta, T., see Ejima, Y. 78, 6

- Mason, K.A., R. Neal, N. Hunter, H. Ariga, K. Ang, L. Milas, CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors **80**, 192
- Mason, K.A., see Raju, U. **80**, 185
- Matsuo, M., see Tanaka, O. **81**, 303
- Matter, M., see Coucke, P.A. **79**, 52
- Matthews, J.H.L., see Gogna, N.K. **81**, 9
- Matzinger, O., see Coucke, P.A. **79**, 52
- Mazal, A., see Caneva, S. **79**, 208
- Mc Bride, W.H., see Debucquoy, A. **80**, 172
- McBride, W.H., see Holzscheiter, M.H. **81**, 233
- McClure, B.E., see Roos, D.E. **80**, 318
- McDermott, L.N., M. Wendling, J.-J. Sonke, M. van Herk, B.J. Mijnheer, Anatomy changes in radiotherapy detected using portal imaging **79**, 211
- McDonough, J., see Machtay, M. **81**, 196
- McIntyre, J.F., see Weber, D.C. **81**, 243
- McKerracher, C., D.I. Thwaites, Notes on the construction of solid-state detectors **79**, 348
- McLaren, D., see Muren, L.P. **80**, 98
- McNair, H.A., see O'Doherty, Ú.M. **79**, 335
- McNicol, K.L., see Huxham, L.A. **78**, 138
- McNutt, T.R., see Kim, Y. **79**, 198
- Medina, J.A., A. Rueda, A.S. de Pasos, J. Contreras, M. Cobo, P. Moreno, M. Benavides, A. Villanueva, E. Alba, A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas **79**, 34
- Meerwaldt, J., see Girinsky, T. **79**, 270
- Mehta, M.P., see Soisson, E.T. **78**, 313
- Mehta, P.S., see Khan, A.J. **81**, 163
- Meier, I., see Zschenker, O. **80**, 236
- Meijer, G.J., H.A. van den Berg, C.W. Hurkmans, P.E. Stijns, J.H. Weterings, Dosimetric comparison of interactive planned and dynamic dose calculated prostate seed brachytherapy **80**, 378
- Meijnders, P., see Girinsky, T. **79**, 270
- Mendes, R., K. Lavrenkov, J.L. Bedford, A. Henrys, S. Ashley, M. Brada, Comparison of forward planning with automated inverse planning for three-dimensional conformal radiotherapy of non-small cell lung cancer without IMRT **78**, 322
- Meng, J., see Samant, R.S. **78**, 101
- Merkx, M.A.W., see Jonathan, R.A. **79**, 288
- Merlet, P., see Guldner, L. **81**, 47
- Meskel, P., see Bues, M. **79**, 70
- Meyer, H.J., Opening lecture of the 25th annual meeting, ESTRO, Leipzig Expensive new therapy and finite resources: An ethical dilemma for doctors and scientists **81**, 227
- Meyer, J., see Guckenberger, M. **79**, 59
- Michalski, W., see Bujko, K. **80**, 4
- Micke, O., see Miller, R.C. **80**, 323
- Mijnheer, B.J., see van Asselen, B. **79**, 162
- Mijnheer, B.J., see Bloemen-van Gurp, E.J. **80**, 288
- Mijnheer, B.J., see McDermott, L.N. **79**, 211
- Milas, L., see Mason, K.A. **80**, 192
- Milas, L., see Raju, U. **80**, 185
- Miles, E., see O'Doherty, Ú.M. **79**, 335
- Miller, R.C., S. Villà, S. Kamer, D. Pasquier, P. Poortmans, O. Micke, T.G. Call, Palliative treatment of Erdheim-Chester disease with radiotherapy: A Rare Cancer Network study **80**, 323
- Miller, R.C., see Ozyar, E. **81**, 39
- Milosevic, M., see Fyles, A. **80**, 132
- Minchinton, A.I., see Huxham, L.A. **78**, 138
- Mini, R., see Vetterli, D. **79**, 101
- Minken, A., see Bosmans, G. **81**, 73
- Minken, A., see De Ruysscher, D. **80**, 307
- Minken, A., see Duisters, C. **79**, 285
- Minken, A.W.H., see Bloemen-van Gurp, E.J. **80**, 288
- Minn, H., see Lindholm, P. **78**, 146
- Minsat, M., see Llácer, C. **78**, 10
- Miralbell, R., see Boehmer, D. **79**, 259
- Mischkus, A., see Eke, I. **80**, 178
- Mizoe, J.-E., see Ishikawa, H. **81**, 57
- Moerland, M.A., see Lagerburg, V. **80**, 73
- Møller, S.P., see Holzscheiter, M.H. **81**, 233
- Molls, M., see Geinitz, H. **79**, 341
- Molls, M., see Goldner, G. **78**, 36
- Moltz, C.C., see Nguyen, N.P. **80**, 302
- Monti, A.F., G. Frigerio, Dosimetric verification of 6 and 18 MV intensity modulated photon beams using a dedicated fluoroscopic electronic portal imaging device (EPID) **81**, 88
- Moppi, G., see Vink, S.R. **80**, 207
- Morash, C., see Cygler, J.E. **80**, 296
- Moreno, P., see Medina, J.A. **79**, 34
- Mori, S., M. Endo, R. Kohno, H. Asakura, K. Kohno, T. Yashiro, S. Komatsu, S. Kandatsu, M. Baba, Respiratory correlated segment reconstruction algorithm towards four-dimensional radiation therapy using carbon ion beams **80**, 341
- Morita, S., see Ishikawa, H. **81**, 57
- Mornex, F., see Chapet, O. **80**, 333
- Moskvin, V., see Spiridovich, S. **78**, 159
- Mouridsen, K., see Buus, S. **78**, 262
- Movsas, B., see Jin, J.-Y. **78**, 177
- Mueller-Klieser, W., see Quennet, V. **81**, 130
- Mueller-Klieser, W., see Yaromina, A. **81**, 122
- Müller, R.-P., see Treuer, H. **81**, 25
- Muller, T., see Geinitz, H. **79**, 341
- Munk, O.L., see Buus, S. **78**, 262
- Munoz, F., see Stasi, M. **80**, 363
- Munshi, A., K.C. Pandey, S.P. Susheela, Letter to the Editor **78**, 109
- Muren, L.P., A.T. Redpath, D. McLaren, J. Rørvik, O.J. Halvorsen, J. Høstmark, A. Bakke, D. Thwaites, O. Dahl, A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy **80**, 98
- Muren, L.P., see Hysing, L.B. **80**, 349
- Muren, L.P., see Redpath, A.T. **81**, 276
- Muzio, N. Di, see Fiorino, C. **78**, 276
- Naczek, E., see Senkus-Konefka, E. **79**, 304
- Nakamatsu, K., see Suzuki, M. **78**, 283
- Nakamura, S., see Sakata, K.-i. **79**, 179
- Nakamura, S., see Yoshioka, Y. **80**, 62
- Nakano, M., see Tanaka, O. **81**, 303
- Naudy, S., see Peignaux, K. **81**, 176
- Nava, L., see Guedea, F. **80**, 57
- Neal, R., see Mason, K.A. **80**, 192
- Nesland, J.M., see Helland, Å. **80**, 230
- Nestle, U., S. Kremp, A.-L. Grosu, Practical integration of [¹⁸F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): The technical basis, ICRU-target volumes, problems, perspectives **81**, 209
- Neubauer, S., see Distel, L.V.R. **81**, 257
- Ngan, S.Y.K., see Leong, T. **78**, 254
- N'guyen, D., see Chapet, O. **80**, 333
- Nguyen Bui, B., see Llácer, C. **78**, 10
- Nguyen, L.M., see Nguyen, N.P. **80**, 302
- Nguyen, N.P., C. Frank, C.C. Moltz, P. Vos, H.J. Smith, P.V. Bhamidipati, U. Karlsson, P.D. Nguyen, A. Alfieri, L.M. Nguyen, C. Lemanski, W. Chan, S. Rose, S. Sallah, Aspiration rate following chemoradiation for head and neck cancer: An underreported occurrence **80**, 302
- Nguyen, P.D., see Nguyen, N.P. **80**, 302
- Ni, M., see Lu, J.-C. **79**, 21
- Nickers, P., B. Thissen, N. Jansen, J.M. Deneufbourg, ¹⁹²Ir or ¹²⁵I prostate brachytherapy as a boost to external beam radiotherapy

- in locally advanced prostatic cancer: A dosimetric point of view **78**, 47
- Nickers, P., L. Coppens, J. de Leval, N. Jansen, J.-M. Deneufbourg, ¹⁹²Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial **79**, 329
- Nicolini, G., see Cozzi, L. **80**, 268
- Niehoff, P., C. Polgar, H. Ostertag, T. Major, Z. Sulyok, B. Kimmig, G. Kovacs, Clinical experience with the MammoSite[®] radiation therapy system for brachytherapy of breast cancer: Results from an international phase II trial **79**, 316
- Niehoff, P., see Major, T. **79**, 321
- Nielsen, H.M., M. Overgaard, C. Grau, A.R. Jensen, J. Overgaard, Loco-regional recurrence after mastectomy in high-risk breast cancer-risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials **79**, 147
- Nielsen, J., see Carl, J. **78**, 199
- Nielsen, M., O. Hansen, W. Vach, Attempts to predict the long-term decrease in lung function due to radiotherapy of non-small cell lung cancer **78**, 165
- Nielsen, S.K., see Tanderup, K. **81**, 105
- Niibe, Y., see Ishiyama, H. **78**, 194
- Nijsten, S., see Duisters, C. **79**, 285
- Nilsson, J., see Kälkner, K.M. **81**, 179
- Nilsson, J., see Kälkner, K.M. **81**, 291
- Nilsson, S., see Kälkner, K.M. **81**, 291
- Nilsson, S., see Kälkner, K.M. **81**, 179
- Nishimura, K., see Yoshioka, Y. **80**, 62
- Nishimura, Y., see Suzuki, M. **78**, 283
- Nishio, M., see Sakata, K.-i. **79**, 179
- Noël, A., see Lorchel, F. **80**, 327
- Nofal, A.N., see Bradley, J.D. **81**, 264
- Nokihara, H., see Sekine, I. **80**, 93
- Nonomura, N., see Yoshioka, Y. **80**, 62
- Noordijk, E., see Girinsky, T. **79**, 270
- Nordsmark, M., J. Loncaster, C. Aquino-Parsons, S.-C. Chou, V. Gebiski, C. West, J.C. Lindegaard, H. Havsteen, S.E. Davidson, R. Hunter, J.A. Raleigh, J. Overgaard, The prognostic value of pimonidazole and tumour pO₂ in human cervix carcinomas after radiation therapy: A prospective international multi-center study **80**, 123
- Norman, A.R., see O'Doherty, Ú.M. **79**, 335
- Notter, M., see Coucke, P.A. **79**, 52
- Nowacki, M.P., see Bujko, K. **80**, 4
- Nulens, A., see Lang, S. **78**, 185
- Nulens, A., see Pötter, R. **78**, 67
- Nüsslin, F., see Baum, C. **78**, 27
- Nutting, C., N. Horlock, R. A'Hern, A. Searle, J. M. Henk, P. Rhys-Evans, K. Harrington, Manually after-loaded ¹⁹²Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer **80**, 39
- Nuyts, S., see De Schutter, H. **80**, 143
- Nyholm, T., J. Olofsson, A. Ahnesjö, M. Karlsson, Photon pencil kernel parameterisation based on beam quality index **78**, 347
- Nyström, H., see Korreman, S.S. **80**, 257
- O, S.K., see Teo, P.M.L. **79**, 27
- Odame, I., see Carret, A.-S. **81**, 33
- O'Doherty, Ú.M., H.A. McNair, A.R. Norman, E. Miles, S. Hooper, M. Davies, N. Lincoln, J. Balyckyi, P. Childs, D.P. Dearnaley, R.A. Huddart, Variability of bladder filling in patients receiving radical radiotherapy to the prostate **79**, 335
- Oechs, K., see Kirisits, C. **81**, 269
- Oei, B., see van der Linden, Y.M. **78**, 245
- Oh, R.-J., see Yoshioka, Y. **80**, 62
- Ohe, Y., T. Kodama, N. Saijo, T. Tamural. Sekine, M. Sumi, Y. Ito, H. Nokihara, N. Yamamoto, H. Kunitoh, Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients **80**, 93
- Ohe, Y., see Sekine, I. **80**, 93
- Okamoto, Y., see Ejima, Y. **78**, 6
- Okumura, M., see Suzuki, M. **78**, 283
- Okuyama, A., see Yoshioka, Y. **80**, 62
- Olive, P.L., see Klokov, D. **80**, 223
- Olofsson, J., see Nyholm, T. **78**, 347
- Olsen, D.R., see Tanderup, K. **79**, 245
- Olsen, D.R., see Tanderup, K. **81**, 105
- Oosterwijk, E., see Jonathan, R.A. **79**, 288
- Orecchia, R., see Cattani, F. **79**, 65
- Orecchia, R., see Ciocca, M. **78**, 213
- Orecchia, R., see Jereczek-Fossa, B.A. **81**, 294
- Orecchia, R., see Spadea, M.F. **79**, 170
- Ortholan, C., see Courdi, A. **79**, 156
- O'Sullivan, B., see Akudugu, J.M. **78**, 17
- Ostertag, H., see Niehoff, P. **79**, 316
- Ota, Y., see Ejima, Y. **78**, 6
- Ottestad, L.O., see Helland, Å. **80**, 230
- Ottestad, W., see Helland, Å. **80**, 230
- Overgaard, J., see Bernier, J. **80**, 109
- Overgaard, J., see Lukacova, S. **80**, 165
- Overgaard, J., see Nielsen, H.M. **79**, 147
- Overgaard, J., see Nordsmark, M. **80**, 123
- Overgaard, M., see Nielsen, H.M. **79**, 147
- Oyen, R., see Dirix, P. **79**, 1
- Oyen, W.J.G., see de Geus-Oei, L.-F. **80**, 51
- Oyen, W.J.G., see Troost, E.G.C. **80**, 157
- Ozsahin, M., see Ozyar, E. **81**, 39
- Ozyar, E., U. Selek, S. Laskar, O. Uzel, Y. Anacak, M. Ben-Arush, S. Polychronopoulou, F. Akman, S.L. Wolden, S. Sarhan, R.C. Miller, M. Ozsahin, U. Abacioğlu, M. Martin, M. Caloglu, L. Scandolaro, E. Szutowicz, I.L. Atahan, Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A Rare Cancer Network study **81**, 39
- Paelinck, L., B. De Smedt, N. Reynaert, M. Coghe, W. De Gersem, C. De Wagter, B. Vanderstraeten, H. Thierens, W. De Neve, Comparison of dose-volume histograms of IMRT treatment plans for ethmoid sinus cancer computed by advanced treatment planning systems including Monte Carlo **81**, 250
- Palmgren, J., see Guedea, F. **80**, 57
- Pandey, K.C., see Munshi, A. **78**, 109
- Pandey, M., see Kumar, S. **78**, 107
- Papiez, L., see Spiridovich, S. **78**, 159
- Papiez, L., see Spiridovich, S. **81**, 309
- Park, S., see Choi, Y. **81**, 158
- Parker, W.A., C.R. Freeman, A simple technique for craniospinal radiotherapy in the supine position **78**, 217
- Pasquier, D., see Miller, R.C. **80**, 323
- Pasquino, M., see Stasi, M. **80**, 363
- Patel, F.D., see Saibishkumar, E.P. **79**, 142
- Paulsen, F., see Thorwarth, D. **80**, 151
- Pawelczyk, I., see Suwinski, R. **80**, 27
- Pearson, A., see Brooker, S. **79**, 45
- Pedersen, A.N., see Korreman, S.S. **80**, 257
- Pedotti, A., see Spadea, M.F. **79**, 170
- Peeters, R., see De Brabandere, M. **79**, 190
- Peeters, W., see Jonathan, R.A. **79**, 288
- Peiffert, D., see Bruna, A. **79**, 75
- Peignaux, K., G. Truc, I. Barillot, A. Ammor, S. Naudy, G. Créhange, P. Maingon, Clinical assessment of the use of the Sonarray system for daily prostate localization **81**, 176

- Pein, F., see Guldner, L. **81**, 47
 Pellegrini, R., see Cozzi, L. **80**, 268
 Penfield Faber, L., see Khan, A.J. **81**, 163
 Perry, G., see Cygler, J.E. **80**, 296
 Petersen, C., see Yaromina, A. **81**, 122
 Petersen, J., see Holzscheiter, M.H. **81**, 233
 Petoukhova, A.L., C.H.J. Terhaard, H. Welleweerd, Does 4 MV perform better compared to 6 MV in the presence of air cavities in the head and neck region? **79**, 203
 Petrow, P., see Lang, S. **78**, 185
 Petrow, P., see Pötter, R. **78**, 67
 Pezner, R.D., A. Liu, C. Han, Y.-J. Chen, T.E. Schultheiss, J.Y.C. Wong, Dosimetric comparison of helical tomotherapy treatment and step-and-shoot intensity-modulated radiotherapy of retroperitoneal sarcoma **81**, 81
 Philippens, M., see Troost, E.G.C. **80**, 157
 Piazzzi, V., see Ciocca, M. **78**, 213
 Pickett, J., see Raju, U. **80**, 185
 Pickles, T., G. Duncan, P. Graham, Re: Hermann et al., Low testosterone levels and Quality of Life **78**, 107
 Pierelli, A., see Fiorino, C. **78**, 276
 Piessens, M., see Kollaard, R.P. **78**, 223
 Pieters, B.R., J.N.B. van der Grient, L.E.C.M. Blank, K. Koedooder, M.C.C.M. Hulshof, T.M. de Reijke, Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants **80**, 69
 Pignol, J.-P., see Hoisak, J.D.P. **78**, 339
 Pijls, M., see De Ruyscher, D. **80**, 307
 Pinkawa, M., J. Silushek, B. Gagel, C. Demirel, B. Asadpour, R. Holy, M.J. Eble, Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer **81**, 284
 Pinkawa, M., K. Fishedick, P. Treusacher, B. Asadpour, B. Gagel, M.D. Piroth, H. Borchers, G. Jakse, M.J. Eble, Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer- a phase II study **78**, 41
 Pintilie, M., see Fyles, A. **80**, 132
 Piroth, M.D., see Pinkawa, M. **78**, 41
 Pitman, A., see Leong, T. **78**, 254
 Pitz, C., see De Ruyscher, D. **80**, 307
 Plataniotis, G.A., see Tsiakalos, M.F. **79**, 131
 Pötter, R., see Bartsch, R. **80**, 313
 Pohl, F., see Guckenberger, M. **79**, 59
 Pokrajac, B., see Syeda, B. **78**, 60
 Polgar, C., see Major, T. **79**, 321
 Polgar, C., see Niehoff, P. **79**, 316
 Polo, A., see Cattani, F. **79**, 65
 Polo, A., see Guedea, F. **80**, 57
 Polychronopoulou, S., see Ozyar, E. **81**, 39
 Poortmans, P., see Boehmer, D. **79**, 259
 Poortmans, P., see Girinsky, T. **79**, 270
 Poortmans, P., see Miller, R.C. **80**, 323
 Pop, L.A.M., see de Geus-Oei, L.-F. **80**, 51
 Porter, L., see Brooker, S. **79**, 45
 Post, W.J., see van der Linden, Y.M. **78**, 245
 Pötter, R., C. Haie-Meder, E.V. Limbergen, I. Barillot, M.D. Brabandere, J. Dimopoulos, I. Dumas, B. Erickson, S. Lang, A. Nulens, P. Petrow, J. Rownd, C. Kirisits, Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology **78**, 67
 Pötter, R., see Georg, P. **80**, 19
 Pötter, R., see Goldner, G. **78**, 36
 Pötter, R., see Kirisits, C. **81**, 269
 Pötter, R., see Kontrisola, K. **81**, 97
 Pötter, R., see Lang, S. **78**, 185
 Pötter, R., see Syeda, B. **78**, 60
 Pötter, R., J. Dimopoulos, B. Bachtiary, G. Sissolak, B. Klos, A. Rheinthaller, C. Kirisits, T.-H. Knocke-Abulesz, 3D conformal HDR-brachy- and external beam therapy plus simultaneous Cisplatin for high-risk cervical cancer: Clinical experience with 3 year follow-up **79**, 80
 Pötzi, R., see Goldner, G. **78**, 36
 Price, P., Molecular imaging to improve radiotherapy **78**, 233
 Qian, P.-D., see Lu, J.-C. **79**, 21
 Quennet, V., A. Yaromina, D. Zips, A. Rosner, S. Walenta, M. Baumann, W. Mueller-Klieser, Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice **81**, 130
 Quennet, V., see Yaromina, A. **81**, 122
 Raju, U., H. Ariga, M. Koto, X. Lu, J. Pickett, D. Valdecanas, K.A. Mason, L. Milas, Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases **80**, 185
 Raleigh, J.A., see Nordsmark, M. **80**, 123
 Raleigh, J.A., see Yaromina, A. **81**, 122
 Rasch, C.R.N., see van den Broek, G.B. **81**, 143
 Redpath, A.T., L.P. Muren, CT-guided intensity-modulated radiotherapy for bladder cancer: Isocentre shifts, margins and their impact on target dose **81**, 276
 Redpath, A.T., see Muren, L.P. **80**, 98
 Reiner, B., see Davis, J.B. **80**, 43
 Remouchamps, V., see Boehmer, D. **79**, 259
 Reynaert, N., see Paelinck, L. **81**, 250
 Rheinthaller, A., see Potter, R. **79**, 80
 Rhys-Evans, P., see Nutting, C. **80**, 39
 Riboldi, M., see Spadea, M.F. **79**, 170
 Richards, G.M., see Soisson, E.T. **78**, 313
 Rodell, A., see Buus, S. **78**, 262
 Rodningen, O.K., see Helland, Å. **80**, 230
 Rodrigues, G., S. Yartsev, J. Chen, E. Wong, D. D'Souza, M. Lock, G. Bauman, G. Grigorov, T. Kron, A comparison of prostate IMRT and helical tomotherapy class solutions **80**, 374
 Rodrigues, G., see Yartsev, S. **78**, 169
 Rodrigus, P., see Vulto, A. **78**, 131
 Roels, S., see Debucquoy, A. **80**, 172
 Roessler, K., see Bartsch, R. **80**, 313
 Rollo Moore, A., A.P. Jim Warrington, E.G.A. Aird, A. Margaret Bidmead, D.P. Dearnaley, A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer **80**, 82
 Romestaing, P., see Chapet, O. **80**, 333
 Rondi, E., see Cattani, F. **79**, 65
 Roos, D.E., A. Wirth, B.H. Burmeister, N.A. Spry, K.J. Drummond, J.A. Beresford, B.E. McClure, Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: Mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05) **80**, 318
 Roos, M., see Wergin, M.C. **79**, 239
 Rørvik, J., see Muren, L.P. **80**, 98
 Rose, S., see Nguyen, N.P. **80**, 302
 Rosenwald, J.-C., see Caneva, S. **79**, 208
 Rosenzweig, K.E., see Chan, M.F. **79**, 218
 Rosner, A., see Quennet, V. **81**, 130
 Rosner, A., see Yaromina, A. **81**, 122
 Roué, A., I.H. Ferreira, J.V. Dam, H. Svensson, J.L.M. Venselaar, The EQUAL-ESTRO audit on geometric reconstruction techniques in brachytherapy **78**, 78

- Rownd, J., see Pötter, R. 78, 67
 Rübel, A., see Handrick, R. 80, 199
 Rudas, M., see Bartsch, R. 80, 313
 Rueda, A., see Medina, J.A. 79, 34
 Russi, E.G., see Pergolizzi, S. 79, 352
- Saarilahti, K., M. Kouri, J. Collan, A. Kangasmäki, T. Atula, H. Joensuu, M. Tenhunen, Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer 78, 270
 Saarilahti, K., M. Kouri, J. Collan, A. Kangasmäki, T. Atula, H. Joensuu, M. Tenhunen, Erratum to "Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer" [Radiother. Oncol. 78 (2006) 270-275] 80, 107
 Sætersdal, A.B., see Helland, Å. 80, 230
 Saibishkumar, E.P., F.D. Patel, S.C. Sharma, G. Karunanidhi, S. Ghoshal, V. Kumar, R. Kapoor, Prognostic value of response to external radiation in stage 1MB cancer cervix in predicting clinical outcomes: A retrospective analysis of 556 patients from India 79, 142
 Saibishkumar, E.P., N. Jha, Sparing submandibular gland by IMRT 80, 106
 Said, H., A. Katzer, M. Flentje, D. Vordermark, Response to a letter to the editor by Le et al. regarding: Osteopontin as toxic marker 78, 230
 Saijo, N., see Sekine, I. 80, 93
 Sakata, K.-i., N. Fuwa, T. Kodaira, K. Aratani, H. Ikeda, M. Takagi, M. Nishio, M. Satoh, S. Nakamura, H. Satoh, M. Hareyama, Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification 79, 179
 Sakiroglu, O., see Guldner, L. 81, 47
 Sakurai, K., see Tanaka, O. 81, 303
 Salem, N., see Guedea, F. 80, 57
 Sallah, S., see Nguyen, N.P. 80, 302
 Salter, B.J., see Fuller, C.D. 81, 65
 Samant, R.S., E. Fitzgibbon, J. Meng, I.D. Graham, Family physicians' perspectives regarding palliative radiotherapy 78, 101
 Sandfort, V., see Eke, I. 80, 178
 Sandison, G., see Spiridovich, S. 81, 309
 Santiago, J., see Machtay, M. 81, 196
 Saoudi, A., see Cygler, J.E. 80, 296
 Sarihan, S., see Ozyar, E. 81, 39
 Sasaki, R., see Ejima, Y. 78, 6
 Satoh, H., see Sakata, K.-i. 79, 179
 Satoh, M., see Sakata, K.-i. 79, 179
 Satoh, T., see Ishiyama, H. 78, 194
 Sauer, R., see Brunner, T.B. 79, 109
 Sauer, R., see Brunner, T.B. 81, 190
 Sauer, R., see Distel, L.V.R. 81, 257
 Sauer, R., see Ernst-Stecken, A. 81, 18
 Scalliet, P., Risk, society and system failure 80, 275
 Scandolaro, L., see Ozyar, E. 81, 39
 Schaart, D.R., see Kollaard, R.P. 78, 223
 Schader, M.B., see Wissink, E.H.J. 80, 214
 Schaefer, U., see Wissink, E.H.J. 80, 214
 Scheithauer, H., see Hehr, T. 80, 33
 Schellens, J.H.M., see Vink, S.R. 80, 207
 Scherpereel, A., see Machtay, M. 81, 196
 Schlumpf, R., see Coucke, P.A. 79, 52
 Schmid, R., see Syeda, B. 78, 60
 Schneider, U., see Stenecker, M. 80, 263
 Schornagel, J.H., see van den Broek, G.B. 81, 143
 Schukro, C., see Syeda, B. 78, 60
 Schultheiss, T.E., see Pezner, R.D. 81, 81
 Schupak, K., see Chan, M.F. 79, 218
 Schwarz, M., see van Asselen, B. 79, 162
 Scott, D., see Bauman, G. 80, 394
 Scrase, C., see Boehmer, D. 79, 259
 Searle, A., see Nutting, C. 80, 39
 Seefeld, F., see Siebert, F.-A. 79, 298
 Selek, U., see Ozyar, E. 81, 39
 Senkus-Konefka, E., E. Naczek, I. Borowska, A. Badzio, J. Jassem, Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer 79, 304
 Seppi, E., see Van den Heuvel, F. 79, 94
 Servois, V., see Kirova, Y.M. 79, 310
 Shahidi, M., N. Kamangari, S. Ashley, D. Cunningham, A. Horwich, Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease 78, 1
 Sham, J.S.T., see Teo, P.M.L. 79, 27
 Shamsaldin, A., see Guldner, L. 81, 47
 Sharma, S.C., see Saibishkumar, E.P. 79, 142
 Sherlock, G., see Helland, Å. 80, 230
 Shibata, T., see Suzuki, M. 78, 283
 Shimazaki, J., see Ishikawa, H. 81, 57
 Shott, S., see Khan, A.J. 81, 163
 Shuvaev, V.V., see Machtay, M. 81, 196
 Sidi, D., see Guldner, L. 81, 47
 Siebert, F.-A., T. Born, S. Haring, F. Seefeld, G. Kovacs, A dosimetric analysis of interstitial intensity modulated implants for pelvic recurrences, base of tongue and orbita tumors with specific references to the ICRU-58 79, 298
 Sillanmäki, L., see Lindholm, P. 78, 146
 Siluscheck, J., see Pinkawa, M. 81, 284
 Simons, J., see De Ruyscher, D. 80, 307
 Sindermann, H., see Vink, S.R. 80, 207
 Siostrzonek, P., see Syeda, B. 78, 60
 Sissolak, G., see Potter, R. 79, 80
 Sixel, K.E., see Hoisak, J.D.P. 78, 339
 Skarsgard, L.D., see Holzscheiter, M.H. 81, 233
 Slevin, N., see Mangar, S. 78, 152
 Slotman, B.J., see Langendijk, J.A. 78, 306
 Slotman, B.J., see Vergeer, M.R. 79, 39
 Smathers, J.B., see Holzscheiter, M.H. 81, 233
 Smith, H.J., see Nguyen, N.P. 80, 302
 Smithers, B.M., see Burmeister, B.H. 81, 136
 Snoep, G., see De Ruyscher, D. 80, 307
 Soejima, T., see Ejima, Y. 78, 6
 Soete, G., D. Verellen, K. Tournel, G. Storme, Setup accuracy of stereoscopic X-ray positioning with automated correction for rotational errors in patients treated with conformal arc radiotherapy for prostate cancer 80, 371
 Soete, G., S. Arcangeli, G. De Meerleer, V. Landoni, V. Fonteyne, G. Arcangeli, W. De Neve, G. Storme, Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity 80, 78
 Soete, G., see Verellen, D. 78, 332
 Sohaib, S.A., see Mangar, S.A. 80, 355
 Soisson, E.T., W.A. Tomé, G.M. Richards, M.P. Mehta, Comparison of linac based fractionated stereotactic radiotherapy and tomotherapy treatment plans for skull-base tumors 78, 313
 Solberg, T.D., see Holzscheiter, M.H. 81, 233
 Solomides, C.C., see Machtay, M. 81, 196
 Song, Y., see Chan, M.F. 79, 218
 Sonke, J.-J., see McDermott, L.N. 79, 211
 Spadea, M.F., G. Baroni, M. Riboldi, B. Tagaste, C. Garibaldi, R. Orecchia, A. Pedotti, Patient set-up verification by infrared optical localization and body surface sensing in breast radiation therapy 79, 170
 Spaepen, M., see De Schutter, H. 80, 143

- Specht, L., see Girinsky, T. **79**, 270
 Specht, L., see Korreman, S.S. **80**, 257
 Spezi, E., D.G. Lewis, Gamma histograms for radiotherapy plan evaluation **79**, 224
 Spies, L., see Kim, Y. **79**, 198
 Spiridovich, S., L. Papiez, M. Langer, G. Sandison, V. Thai, High density dental materials and radiotherapy planning: Comparison of the dose predictions using superposition algorithm and fluence map Monte Carlo method with radiochromic film measurements **81**, 309
 Spiridovich, S., L. Papiez, V. Moskvina, P. Desrosiers, Evaluation of underdosage in the external photon beam radiotherapy of glottic carcinoma: Monte Carlo study **78**, 159
 Sprung, C.N., see Distel, L.V.R. **81**, 257
 Spry, N., see Burmeister, B.H. **81**, 136
 Spry, N., see Gogna, N.K. **81**, 9
 Spry, N.A., see Roos, D.E. **80**, 318
 Stamm, B., see Coucke, P.A. **79**, 52
 Starman, M., see Duisters, C. **79**, 285
 Starzewski, J., see Suwinski, R. **80**, 27
 Stasi, M., F. Munoz, C. Fiorino, M. Pasquino, B. Baiotto, P. Marini, G. Malinverni, R. Valdagni, P. Gabriele, Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer **80**, 363
 Stathakis, S., see Caneva, S. **79**, 208
 Stathakis, S., see Tsiakalos, M.F. **79**, 131
 Steenland, E., see van der Linden, Y.M. **78**, 245
 Steger, G.G., see Bartsch, R. **80**, 313
 Steneker, M., A. Lomax, U. Schneider, Intensity modulated photon and proton therapy for the treatment of head and neck tumors **80**, 263
 Stijns, P.E., see Meijer, G.J. **80**, 378
 Stock, M., see Kontriso, K. **81**, 97
 Stoeckle, E., see Ll  cer, C. **78**, 10
 Storme, G., see Soete, G. **80**, 371
 Storme, G., see Soete, G. **80**, 78
 Storme, G., see Verellen, D. **78**, 332
 Streichert, T., see Zschenker, O. **80**, 236
 Sturm, V., see Treuer, H. **81**, 25
 Stys-Norman, D., see Ung, Y.C. **80**, 13
 Sugimura, K., see Ejima, Y. **78**, 6
 Suhag, V., V. Kaushal, R. Yadav, B.P. Das, Comparison of simulator-CT versus simulator fluoroscopy versus surface marking based radiation treatment planning: A prospective study by three-dimensional evaluation **78**, 84
 Sulyok, Z., see Niehoff, P. **79**, 316
 Sumi, M., see Sekine, I. **80**, 93
 Sumida, I., see Yoshioka, Y. **80**, 62
 Sun, J., see Machtay, M. **81**, 196
 Sunaoka, M., see Tajiri, M. **80**, 391
 Susheela, S.P., see Munshi, A. **78**, 109
 Suwinski, R., J. Wydmanski, I. Pawelczyk, J. Starzewski, A pilot study of accelerated preoperative hyperfractionated pelvic irradiation with or without low-dose preoperative prophylactic liver irradiation in patients with locally advanced rectal cancer **80**, 27
 Suzuki, M., Y. Nishimura, K. Nakamatsu, M. Okumura, H. Hashiba, R. Koike, S. Kanamori, T. Shibata, Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV)- and planning organs at risk volume (PRV)-margins **78**, 283
 Svensson, H., see Rou  , A. **78**, 78
 Sydes, M.R., see Mangar, S.A. **80**, 355
 Syed, A., see Fyles, A. **80**, 132
 Syeda, B., C. Schukro, C. Kirisits, I. Lang, P. Siostrzonek, M. Gottsauner-Wolf, B. Pokrajac, R. Schmid, N. Yahya, R. P  tter, D. Glogar, Randomized blinded clinical trial of intracoronary brachytherapy with ⁹⁰Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients **78**, 60
 Sykes, A., see Mangar, S. **78**, 152
 Sz  kely, G., see Davis, J.B. **80**, 43
 Sze, W.K., see Teo, P.M.L. **79**, 27
 Sze, W.M., see Teo, P.M.L. **79**, 27
 Szutowicz, E., see Ozyar, E. **81**, 39
 Tabori, U., see Carret, A.-S. **81**, 33
 Tagaste, B., see Spadea, M.F. **79**, 170
 Tajiri, M., Y. Tokiya, J. Uenishi, M. Sunaoka, K. Watanabe, New shielding materials for clinical electron beams **80**, 391
 Takagi, M., see Sakata, K.-i. **79**, 179
 Tamura, T., see Sekine, I. **80**, 93
 Tanaka, O., S. Hayashi, K. Sakurai, M. Matsuo, M. Nakano, S. Maeda, H. Hoshi, T. Deguchi, Importance of the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostate brachytherapy **81**, 303
 Tanderup, K., D.R. Olsen, C. Grau, Dose painting: Art or science? **79**, 245
 Tanderup, K., J.J. Christensen, J. Granfeldt, J.C. Lindegaard, Geometric stability of intracavitary pulsed dose rate brachytherapy monitored by in vivo rectal dosimetry **79**, 87
 Tanderup, K., T.P. Hellebust, H.B. Honor  , S.K. Nielsen, D.R. Olsen, C. Grau, J.C. Lindegaard, Dose optimisation in single plane interstitial brachytherapy **81**, 105
 ten Velde, G., see De Ruyscher, D. **80**, 307
 Tenhunen, M., see Saarilahti, K. **78**, 270
 Tenhunen, M., see Saarilahti, K. **80**, 107
 Teo, P.M.L., S.F. Leung, S.Y. Tung, B. Zee, J.S.T. Sham, A.W.M. Lee, W.H. Lau, W.H. Kwan, T.W. Leung, D. Chua, W.M. Sze, J.S.K. Au, K.H. Yu, S.K. O, D. Kwong, T.K. Yau, S.C.K. Law, W.K. Sze, G. Au, A.T.C. Chan, Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: A study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG) **79**, 27
 Terhaard, C.H.J., see Petoukhova, A.L. **79**, 203
 Thai, V., see Spiridovich, S. **81**, 309
 Thalmann, S., see Vetterli, D. **79**, 101
 Thames, H.D., see Krause, M. **80**, 112
 Thames, H.D., see Yaromina, A. **81**, 122
 Thamm, R., see Geinitz, H. **79**, 341
 Theodorou, K., see Tsiakalos, M.F. **79**, 131
 Thierens, H., see Paelinck, L. **81**, 250
 Thierens, H., see Vanderstraeten, B. **79**, 249
 Thissen, B., see Nickers, P. **78**, 47
 Thomas Jr., C.R., see Fuller, C.D. **81**, 65
 Thomas, G., Cervical cancer: Treatment challenges in the developing world **79**, 139
 Thomas, L., see Bruna, A. **79**, 75
 Thomas, L., see Ll  cer, C. **78**, 10
 Thornton, A.F., see Weber, D.C. **81**, 243
 Thorwarth, D., S.-M. Eschmann, F. Holzner, F. Paulsen, M. Alber, Combined uptake of [¹⁸F]FDG and [¹⁸F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients **80**, 151
 Thwaites, D., see Muren, L.P. **80**, 98
 Thwaites, D.I., see McKerracher, C. **79**, 348
 Tirona, R., see Hoisak, J.D.P. **78**, 339
 Tokiya, Y., see Tajiri, M. **80**, 391
 Tom  , W.A., see Soisson, E.T. **78**, 313
 Tome, W.A., see Kim, Y. **79**, 198
 Tomsej, M., see Geets, X. **78**, 291
 Tosi, G., see Cattani, F. **79**, 65
 Tosi, G., see Ciocca, M. **78**, 213
 Tournel, K., see Soete, G. **80**, 371

- Tournel, K., see Verellen, D. 78, 332
 Trenka, K., see Bauman, G. 80, 394
 Trenka, K., see Yartsev, S. 78, 169
 Treuer, H., M. Kocher, M. Hoevels, S. Hunsche, K. Luyken, M. Maarouf, J. Voges, R.-P. Müller, V. Sturm, Impact of target point deviations on control and complication probabilities in stereotactic radiosurgery of AVMs and metastases 81, 25
 Treusacher, P., see Pinkawa, M. 78, 41
 Tripcony, L., see Gogna, N.K. 81, 9
 Troost, E.G.C., P. Laverman, J.H.A.M. Kaanders, M. Philippons, J. Lok, W.J.G. Oyen, A.J. van der Kogel, O.C. Boerman, J. Bussink, Imaging hypoxia after oxygenation-modification: Comparing [¹⁸F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors 80, 157
 Truc, G., see Peignaux, K. 81, 176
 Tsiakalos, M.F., S. Stathakis, G.A. Plataniotis, C. Kappas, K. Theodorou, Monte Carlo dosimetric evaluation of high energy vs low energy photon beams in low density tissues 79, 131
 Tsiakalos, M.F., see Caneva, S. 79, 208
 Tsuji, H., see Ishikawa, H. 81, 57
 Tsujii, H., see Ishikawa, H. 81, 57
 Tucker, H.L., see Mangar, S.A. 80, 355
 Tung, S.Y., see Teo, P.M.L. 79, 27
 Turner, S.L., see Gogna, N.K. 81, 9
- Uemae, M., see Ishiyama, H. 78, 194
 Uenishi, J., see Tajiri, M. 80, 391
 Uggerhøj, U.I., see Holzscheiter, M.H. 81, 233
 Ung, Y.C., E. Yu, C. Falkson, A.E. Haynes, D. Stys-Norman, W.K. Evans, The role of radiation therapy in malignant pleural mesothelioma: A systematic review 80, 13
 Uzel, O., see Ozyar, E. 81, 39
- Vach, W., see Nielsen, M. 78, 165
 Valavaara, R., see Lindholm, P. 78, 146
 Valdaghi, R., see Stasi, M. 80, 363
 Valdecanas, D., see Raju, U. 80, 185
 van Asselen, B., M. Schwarz, C. van Vliet-Vroegindeweij, J.V. Lebesque, B.J. Mijnheer, E.M.F. Damen, Intensity-modulated radiotherapy of breast cancer using direct aperture optimization 79, 162
 van Baardwijk, A., see De Ruyscher, D. 80, 307
 van den Berg, H.A., see Meijer, G.J. 80, 378
 van den Brekel, M.W.M., see van den Broek, G.B. 81, 143
 van den Broek, G.B., A.J.M. Balm, M.W.M. van den Brekel, M. Hauptmann, J.H. Schornagel, C.R.N. Rasch, Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer 81, 143
 Van den Heuvel, F., see Brabandere, M. De 79, 190
 Van den Heuvel, F., J. Fugazzi, E. Seppi, J.D. Forman, Clinical application of a repositioning scheme, using gold markers and electronic portal imaging 79, 94
 van der Grient, J.N.B., see Pieters, B.R. 80, 69
 van der Kogel, A.J., see Jonathan, R.A. 79, 288
 van der Kogel, A.J., see Troost, E.G.C. 80, 157
 van der Linden, Y.M., E. Steenland, H.C. van Houwelingen, W.J. Post, B. Oei, C.A.M. Marijnen, J.W.H. Leer, Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: Results on survival in the Dutch Bone Metastasis Study 78, 245
 van der Maazen, R., see Girinsky, T. 79, 270
 van der Marel, H., see Kollaard, R.P. 78, 223
 Van Dyk, J., see Langan, A.R. 79, 231
 Van Dyk, J., see Yartsev, S. 78, 169
 van Haren, E., see De Ruyscher, D. 80, 307
 van Herk, M., see McDermott, L.N. 79, 211
 van Houwelingen, H.C., see van der Linden, Y.M. 78, 245
 van Kleffens, H.J., see Kollaard, R.P. 78, 223
 Van Limbergen, E., see Lang, S. 78, 185
 Van Poppel, H., see Dirix, P. 79, 1
 van Vliet-Vroegindeweij, C., see Asselen, B. van 79, 162
 van Vulpen, M., see Lagerburg, V. 80, 73
 van Zijtveld, M., M.L.P. Dirkx, H.C.J. de Boer, B.J.M. Heijmen, Dosimetric pre-treatment verification of IMRT using an EPID; clinical experience 81, 168
 Vander Poorten, V., see De Schutter, H. 80, 143
 Vanderstraeten, B., W. Duthoy, W. De Gersem, W. De Neve, H. Thierens, [¹⁸F]fluoro-deoxy-glucose positron emission tomography ([¹⁸F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer 79, 249
 Vanderstraeten, B., see Paelinck, L. 81, 250
 Vanetti, E., see Cozzi, L. 80, 268
 Vargas, C., see Hugo, G. 78, 326
 Vavassori, A., see Cattani, F. 79, 65
 Vavassori, A., see Ciocca, M. 78, 213
 Vavassori, A., see Jereczek-Fossa, B.A. 81, 294
 Velders, M., see Bosmans, G. 81, 73
 Venselaar, J.L.M., see Roué, A. 78, 78
 Verbrugge, I., see Wissink, E.H.J. 80, 214
 Verellen, D., K. Tournel, N. Linthout, G. Soete, T. Wauters, G. Storme, Importing measured field fluences into the treatment planning system to validate a breathing synchronized DMLC-IMRT irradiation technique 78, 332
 Verellen, D., see Soete, G. 80, 371
 Vergeer, M.R., P. Doornaert, C.R. Leemans, J. Buter, B.J. Slotman, J.A. Langendijk, Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation 79, 39
 Verheij, M., see Vink, S.R. 80, 207
 Verheij, M., see Wissink, E.H.J. 80, 214
 Veronesi, P., see Ciocca, M. 78, 213
 Veronesi, U., see Ciocca, M. 78, 213
 Verschueren, T., see De Ruyscher, D. 80, 307
 Verschueren, T., see Duisters, C. 79, 285
 Vetterli, D., S. Thalmann, F. Behrensmeier, L. Kemmerling, E.J. Born, R. Mini, R.H. Greiner, D.M. Aebersold, Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode 79, 101
 Vieira, S.C., R.A. Bolt, M.L.P. Dirkx, A.G. Visser, B.J.M. Heijmen, Fast, daily linac verification for segmented IMRT using electronic portal imaging 80, 86
 Vikram, B., see Coffey, M. 81, 324
 Villà, S., see Miller, R.C. 80, 323
 Villain, E., see Guldner, L. 81, 47
 Villanueva, A., see Medina, J.A. 79, 34
 Vink, S.R., J.H.M. Schellens, J.H. Beijnen, H. Sindermann, J. Engel, R. Dubbelman, G. Moppi, M.J.X. Hillebrand, H. Bartelink, M. Verheij, Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours 80, 207
 Vink, S.R., see Wissink, E.H.J. 80, 214
 Visser, A.G., see Vieira, S.C. 80, 86
 Voges, J., see Treuer, H. 81, 25
 Vordermark, D., see Guckenberger, M. 79, 59
 Vordermark, D., see Said, H. 78, 230
 Vos, P., see Nguyen, N.P. 80, 302
 Votron, L., see Llacer, C. 78, 10
 Vranjes, S., see Holzscheiter, M.H. 81, 233
 Vulto, A., M. Louwman, P. Rodrigus, J.W.W. Coebergh, Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands, 1988-2002 78, 131

- Wachter, S., see Goldner, G. 78, 36
 Wachter-Gerstner, N., see Goldner, G. 78, 36
 Wakatsuki, M., see Ishikawa, H. 81, 57
 Walczak, H., see Wissink, E.H.J. 80, 214
 Waldron, J.N., see Akudugu, J.M. 78, 17
 Walenta, S., see Quennet, V. 81, 130
 Walenta, S., see Yaromina, A. 81, 122
 Wambersie, A., see Goldner, G. 78, 36
 Wanders, S., see De Ruyscher, D. 80, 307
 Wanders, S., see Duisters, C. 79, 285
 Wang, X., see Beddar, A.S. 78, 207
 Watanabe, K., see Tajiri, M. 80, 391
 Wauters, T., see Verellen, D. 78, 332
 Webb, S., see Mangar, S.A. 80, 355
 Weber, D.C., A.W. Chan, S. Lessell, J.F. McIntyre, S.I. Goldberg, M.R. Bussiere, M.M. Fitzek, A.F. Thornton, T.F. DeLaney, Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons 81, 243
 Wei, B.-Q., see Lu, J.-C. 79, 21
 Wei, Q., see Lu, J.-C. 79, 21
 Weitmann, H.-D., see Bartsch, R. 80, 313
 Welleweerd, H., see Petoukhova, A.L. 79, 203
 Welz, S., see Hehr, T. 80, 33
 Wendling, M., see McDermott, L.N. 79, 211
 Wenzel, C., see Bartsch, R. 80, 313
 Wergin, M.C., M. Roos, N. Inteeworn, D. Luluhova, K. Allemann, B. Kaser-Hotz, The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome 79, 239
 West, C., see Nordsmark, M. 80, 123
 Weterings, J.H., see Meijer, G.J. 80, 378
 Wijffels, K.I.E.M., see Jonathan, R.A. 79, 288
 Wilkinson, K., see Coffey, M. 81, 324
 Wirth, A., see Roos, D.E. 80, 318
 Wissink, E.H.J., I. Verbrugge, S.R. Vink, M.B. Schader, U. Schaefer, H. Walczak, J. Borst, M. Verheij, TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy 80, 214
 Withers, H.R., see Holzscheiter, M.H. 81, 233
 Withers, R., see Dirix, P. 79, 1
 Wolden, S.L., see Ozyar, E. 81, 39
 Wolf, D., see Lorchel, F. 80, 327
 Wong, A., see Fuller, C.D. 81, 65
 Wong, E., see Bauman, G. 80, 394
 Wong, E., see Rodrigues, G. 80, 374
 Wong, E., see Yartsev, S. 78, 169
 Wong, J.W., see Hugo, G. 78, 326
 Wong, J.Y.C., see Pezner, R.D. 81, 81
 Wong, M., see Holzscheiter, M.H. 81, 233
 Wouters, B.G., see Holzscheiter, M.H. 81, 233
 Wrona, A., see Zschenker, O. 80, 236
 Wunder, J.S., see Akudugu, J.M. 78, 17
 Wydmanski, J., see Suwinski, R. 80, 27
 Yadav, R., see Suhag, V. 78, 84
 Yahya, N., see Syeda, B. 78, 60
 Yamamoto, N., see Sekine, I. 80, 93
 Yamazaki, H., see Yoshioka, Y. 80, 62
 Yan, D., see Hugo, G. 78, 326
 Yanagi, T., see Ishikawa, H. 81, 57
 Yang, C.-H., see Chien, C.-R. 78, 110
 Yaromina, A., D. Zips, H.D. Thames, W. Eicheler, M. Krause, A. Rosner, M. Haase, C. Petersen, J.A. Raleigh, V. Quennet, S. Walenta, W. Mueller-Klieser, M. Baumann Pimonidazole labeling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies 81, 122
 Yarnold, J., see Brooker, S. 79, 45
 Yaromina, A., see Quennet, V. 81, 130
 Yartsev, S., J. Chen, E. Yu, T. Kron, G. Rodrigues, T. Coad, K. Trenka, E. Wong, G. Bauman, J. Van Dyk, Comparative planning evaluation of intensity-modulated radiotherapy techniques for complex lung cancer cases 78, 169
 Yartsev, S., see Cozzi, L. 80, 268
 Yartsev, S., see Rodrigues, G. 80, 374
 Yashiro, T., see Mori, S. 80, 341
 Yau, T.K., see Teo, P.M.L. 79, 27
 Yeung, I.W.T., see Langan, A.R. 79, 231
 Yin, F.-F., see Jin, J.-Y. 78, 177
 Yorke, E., see Chan, M.F. 79, 218
 Yorke, E., see Ling, C.C. 78, 119
 Yoshioka, Y., K. Konishi, R.-J. Oh, I. Sumida, H. Yamazaki, S. Nakamura, K. Nishimura, N. Nonomura, A. Okuyama, T. Inoue, High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer 80, 62
 Yu, E., see Ung, Y.C. 80, 13
 Yu, E., see Yartsev, S. 78, 169
 Yu, K.H., see Teo, P.M.L. 79, 27
 Yuen, K., see Leong, T. 78, 254
 Zee, B., see Teo, P.M.L. 79, 27
 Zefkili, S., see Caneva, S. 79, 208
 Zerini, D., see Jereczek-Fossa, B.A. 81, 294
 Zhang, Y.-Q., see Lu, J.-C. 79, 21
 Zielinski, C.C., see Bartsch, R. 80, 313
 Zimmermann, F., see Goldner, G. 78, 36
 Zimmermann, F.B., see Geinitz, H. 79, 341
 Zips, D., see Krause, M. 80, 112
 Zips, D., see Quennet, V. 81, 130
 Zips, D., see Yaromina, A. 81, 122
 Zschenker, O., K. Borgmann, T. Streichert, I. Meier, A. Wrona, E. Dikomey, Lymphoblastoid cell lines differing in p53 status show clear differences in basal gene expression with minor changes after irradiation 80, 236
 Zusag, T.W., see Khan, A.J. 81, 163

Cumulative subject index

Volumes 78–81 (2006)

-
- Accelerated 79, 34
 - Accelerated fractionated radiation 81, 243
 - Accelerated radiotherapy 78, 146
 - Acceleration 80, 33
 - Adaptive radiotherapy 78, 291
 - Adhesion 80, 178
 - Adriamycin 81, 47
 - Advanced breast cancer 80, 313
 - Adverse events 78, 298
 - Affymetrix 80, 236
 - Age 79, 142
 - Air cavity effects 79, 203
 - Air-cavity 79, 208
 - AMOA 80, 268
 - Anal canal 79, 59
 - Anatomy changes 79, 211
 - Angiogenesis 80, 132
 - Anticancer drugs 80, 112
 - Antioxidant enzymes 81, 196
 - Antiproton 81, 233
 - Apoptosis 80, 199, 214; 81, 196
 - Arteriovenous malformation 81, 25
 - Aspiration 80, 302
 - ATM 79, 109; 81, 257
 - Automatic 3D delineation of PET images 80, 43

 - Baltas phantom 78, 78
 - Base of skull 78, 313
 - Bcl-2 proteins 80, 199
 - Beam quality index 78, 347
 - Beta sources 78, 223
 - Bladder 81, 294
 - Bladder filling 79, 335
 - Bladder transitional cell carcinoma 81, 9
 - Bladder volume 79, 335
 - Body frame 81, 97
 - Bone metastases 78, 245; 79, 278
 - Bowel 80, 349
 - Bowel sparing 80, 19
 - Brachytherapy 78, 10, 47, 53, 67, 194, 223; 79, 75, 87, 185, 316, 329; 80, 39, 62, 378; 81, 105, 179, 269, 291
 - Brachytherapy applicator 78, 207
 - Brain 79, 109
 - Brain metastases 80, 313; 81, 18, 25
 - Breast 79, 162
 - Breast cancer 78, 213; 79, 147, 156, 170, 310, 316; 80, 257
 - Breath hold 81, 97
 - Breathing synchronized irradiation 78, 332

 - CA IX 80, 143
 - Cancer 78, 131
 - Cancer cervix 79, 142
 - Cancer outcomes 78, 95
 - Cancer patients 81, 257
 - Cancer risk 81, 257
 - Canine 79, 239
 - Carbogen 80, 51, 157

 - Carbon ion therapy 81, 57
 - Carbon-beam 80, 341
 - Carbonic anhydrase IX 79, 288
 - Cardiac abnormalities 81, 47
 - Catalase 81, 196
 - Catheter displacement 80, 69
 - Cdks 80, 185
 - Cervical cancer 79, 80
 - Cervical carcinoma 79, 87
 - Cervix 78, 185; 80, 138; 81, 105
 - Cervix cancer 78, 67; 80, 132; 81, 269
 - Chemoradiation 80, 33, 302; 81, 9, 143
 - Chemoradiotherapy 78, 236; 80, 138
 - Chemoresponse 80, 192
 - Chemotherapy 78, 1; 81, 33
 - Childhood cancer 81, 47
 - Children 81, 33
 - Chromosomal aberrations 81, 257
 - Cisplatin 79, 80; 80, 33
 - Clinical trials 80, 82
 - Clonogenic tumour cells 80, 112
 - Combined modality treatment 79, 270
 - Combined treatment 80, 207
 - Co-morbidity 78, 123
 - Complications 78, 91
 - Computerised tomography (CT) 81, 179
 - Cone-beam CT 78, 119
 - Conformal radiation therapy 79, 341
 - Conformal radiation treatment 78, 169
 - Conformal radiotherapy 78, 36; 80, 355, 363, 371
 - Connective tissue diseases 78, 123
 - Contrast agent 81, 158
 - Convolution 81, 309
 - Convolution superposition algorithm 81, 315
 - Coronary artery disease 78, 60
 - Correlation study 80, 327
 - Corticosteroid 80, 93
 - Coverage probabilities 78, 27
 - CpG oligodeoxynucleotides 80, 192
 - Craniospinal irradiation 78, 217
 - CT 78, 84
 - CT images 78, 177
 - CT scan 79, 310; 80, 307
 - CT tube potential 81, 206
 - CT/MRI fusion 81, 303
 - CT-scan 78, 291; 81, 190
 - CTV 79, 15
 - Cyberknife 80, 268

 - 3D conformal radiotherapy 81, 294
 - 3D HDR-brachytherapy 79, 80
 - 3D imaging 78, 67
 - 4D 78, 326
 - 4D CT 81, 73
 - 4D CT imaging 81, 264
 - Definitive radiotherapy 79, 156
 - Dental 81, 309

- Detectors 78, 223
 Diabetic mellitus 78, 60
 Digital autoradiography 80, 157
 Direct aperture optimisation 79, 162
 Displacement kit 81, 291
 DNA repair 80, 223
 Dose algorithm 79, 208
 Dose calculation 80, 385; 81, 158
 Dose distribution 79, 304
 Dose homogeneity and conformality 79, 321
 Dose optimisation 81, 105
 Dose perturbation 78, 159
 Dose volume histogram 81, 105
 Dose volume parameters 78, 67
 Dose–response 78, 236; 79, 27
 Dose–volume analysis 78, 169
 Dose–volume histogram (DVH) 80, 363; 81, 250; 294
 Dosimetric verification 81, 315
 Dosimetry 78, 41, 47, 194, 223; 79, 185
 Dynamic conformal arcs 81, 294
 Dynamic dose calculation 80, 378
- Education 78, 101
 EGFR 80, 178
 Elderly patients 79, 156
 Electron beam 80, 288; 391
 Electron density 81, 206
 Electronic equilibrium 79, 203
 Electronic portal imaging 79, 94
 Electrons 78, 213
 End-inspiration 80, 257
 Endorectal balloon 81, 184
 Endoscopy 78, 36
 Energy choice 79, 131
 Environmental pollution 80, 391
 EPID 79, 101, 211; 80, 86; 81, 168
 Erdheim–Chester disease 80, 323
 Erucylphosphocholine 80, 199
 Erufosine 80, 199
 Esophageal cancer 80, 327
 Ethmoid sinus 81, 250
 EUD 78, 313
 Evaluation 79, 224
 Experimental endpoints 80, 112
 Expression profiles 80, 230
 External audit 78, 78
 External beam radiotherapy 81, 151
 External radiation 79, 142
 Extrapleural pneumonectomy 79, 218
- [18F]FDG-PET 79, 249
 Family physicians 78, 101
 Favourable survival 78, 245
 FDG 80, 151; 81, 209
 FDG-PET 78, 291; 80, 43
 Fecal continence 79, 341
 Fibroblasts 78, 17
 Fibrosis 79, 45
 Filmless planning 78, 53
 Flavopiridol 80, 185
 FLT 81, 209
 Fluence map 81, 309
 [¹⁸F]Fluorodeoxyglucose 80, 51
 [¹⁸F]Fluoromisonidazole 80, 157
 Fluoroscopic portal imaging device 81, 88
 Fluoroscopy 78, 84
- FMISO 80, 151
 Follow-up clinics 78, 95
 Follow-up timing 78, 95
 FOXO3A 80, 199
 Fractionated irradiation 81, 130
 Fractionated radiation 81, 122
 Fractionation 79, 115; 80, 223
 Functional imaging-based radiotherapy planning 80, 43
- Gallbladder cancer 81, 65
 Gamma index 79, 224
 Gating 78, 332; 80, 257, 327
 Gene array 80, 236
 Gene expression profile 80, 236
 Geometric reconstruction 78, 78
 Glucose transporter 79, 288
 GLUT-1 80, 143
 Gross residual tumor 79, 142
 Guidelines 79, 15, 259
 Gynecological malignancies 80, 19
- γ H2AX 80, 223
 HAM applicator 78, 207
 HDR-IORT 78, 207
 Head and neck 78, 159; 79, 34, 198; 81, 309
 Head and neck cancer 78, 152, 270, 306; 79, 39, 249, 288; 80, 33, 39, 302; 81, 151, 158
 Head-and-neck cancer 78, 146; 80, 51, 151
 Head and neck IMRT 78, 283
 Head and neck neoplasms 78, 298; 81, 143
 Head and neck radiotherapy 78, 276
 Head and neck squamous cell carcinomas 81, 130
 Head and neck tumors 79, 304
 Head neck 79, 15
 Heart 80, 333
 Helical 81, 264
 Helical tomotherapy 80, 268; 81, 81
 Heterogeneities 79, 131; 81, 122
 Heterogeneity correction 79, 208; 81, 206
 High LET 81, 233
 High-dose-rate 80, 62
 High-dose-rate brachytherapy 78, 41
 High-grade glioma 81, 33
 Histiocytosis 80, 323
 HNSCC 78, 291; 80, 143
 Hodgkin lymphoma 79, 270
 Hodgkin's disease 78, 1
 Hounsfield unit 81, 206
 Human tumor xenografts 81, 122, 130
 Hyperbaric oxygen 78, 91
 Hyperfractionated 79, 34
 Hyperfractionation 79, 52; 80, 27, 33
 Hypofractionation 79, 156; 80, 78; 81, 97
 Hypo-fractionation 78, 119
 Hypofractionated radiotherapy 81, 57
 Hypofractionated therapy 81, 18
 Hypoxia 78, 138; 79, 288; 80, 132, 138, 151, 157; 81, 122, 209
 Hypoxia marker 80, 123
- ¹²⁵I 78, 47, 194; 79, 65; 80, 378
 ICRU-58 79, 298
 IGRT 78, 119
 ILK 80, 178
 Image distortions 78, 53
 Image guided radiotherapy 79, 259
 Image quality 80, 341

- Image-guidance 78, 119, 326
Image-guided radiation therapy 78, 332
Image-guided radiotherapy 81, 65, 276
Imaging 79, 259
Immobilization 81, 184
IMRT 78, 27, 262, 276, 313; 79, 59, 101, 162, 218, 249, 259; 80, 19, 263, 333, 385; 81, 65, 151, 176, 250
In vivo 79, 109; 80, 230
In vivo dosimetry 78, 213; 80, 288, 296
Incidents 80, 282
Individual sensitivity 81, 257
Industrial radiosensitivity 80, 236
In-field control 79, 179
Inflammation 81, 196
Infrared localization 79, 170
Insulin 81, 112
Intensity modulated brachytherapy 79, 298
Intensity modulated radiation therapy 81, 158
Intensity modulated radiotherapy 78, 270; 79, 122; 80, 86; 81, 88, 168
Intensity-modulated photon therapy 80, 268
Intensity-modulated radiation therapy 81, 81
Intensity-modulated radiotherapy 81, 276
Intensity-modulated radiotherapy 80, 98; 81, 151
Intercomparison 78, 185
Interface dosimetry 78, 159
Interfraction motion 78, 326; 81, 184
Internal mammary chain 79, 310
Internal target volume (ITV) 78, 177; 80, 327
Interstitial 81, 105
Interstitial brachytherapy 79, 298
Interstitial breast implants 79, 321
Interstitial fluid pressure 80, 132
Intestine 80, 349
Intra-arterial infusions 81, 143
Intracavitary brachytherapy 78, 185
Intracoronary brachytherapy 78, 60
Intracoronary radiation 78, 60
Involved-field radiation treatment 79, 270
Involved-node radiotherapy 79, 270
Iodine-125 79, 185
Ionizing radiation 80, 178
IORT 78, 207, 213
¹⁹²Ir 78, 47
Iridium192 79, 329
Irradiation 80, 250; 81, 112
Isocentre shifts 81, 276
Isolated neck recurrence 81, 1
- Kidney 79, 115
- Lactate imaging 81, 130
Larynx and maxillary sinus 79, 203
Late visual complications 81, 243
Lead substitute 80, 391
Lens sparing 78, 6
Liver 79, 109
Local control 79, 27
Local tumor control 81, 122, 130
Localization 78, 199
Localized prostate cancer 80, 363
Loco-regional failure 79, 147
Low dose hypersensitivity 79, 115
Low dose rate 79, 329
LQ model 78, 185
Lung 80, 333
Lung cancer 78, 322, 339; 79, 122, 285; 80, 93; 81, 73, 97, 163, 209, 264
Lung fibrosis 81, 196
Lung function 78, 165
Lung neoplasms 78, 326
Lung radiotherapy 78, 177
Lymphadenopathy 80, 39
Lymphatic metastasis 81, 190
Lymphoma 78, 1
- Magnetic resonance imaging 79, 21
Malignant 78, 199
Malignant pleural mesothelioma 80, 13
MammoSite brachytherapy 79, 321
MammoSite® 79, 316
Mastectomy 79, 147
Mature T/NK-cell lymphoma 79, 179
Maximum intensity projection 81, 264
Mediastinum 80, 307
Medulloblastoma 78, 217
Melanoma 81, 136
Mesothelioma 79, 218
Metal artifacts 79, 198
Micronuclei 79, 231
Microsatellite alterations 80, 143
Microvascular density 79, 288
Mitochondria 80, 214
Mitomycin-C 80, 33
Mobile linear accelerator 78, 213
Modelling 78, 165
Molecular targeting 80, 112
Monitor unit verification 78, 347
Monotherapy 80, 62
Monte Carlo 78, 159; 81, 250, 309
Morbidity 78, 41, 298
MOSFET 78, 213; 80, 288
MOSFET detectors 80, 296
Mouse model 80, 250
MR 78, 185
MRI 78, 291; 80, 73; 81, 269
Mucosa-associated lymphoid tissue lymphoma 78, 6
Multimodality imaging 78, 291
- Nasopharyngeal carcinoma 79, 21, 27
Nasopharynx cancer 81, 39
NBS1 81, 257
Needle insertion 80, 73
Neoadjuvant 78, 236
Neoplasm 78, 199
Neurovascular structures 78, 10
Nicotinamide 80, 51
Nodal disease 81, 136
Node levels 79, 15
Non coplanar 80, 333
Non-coplanar arc therapy 81, 151
Non-Hodgkin's lymphoma 79, 179
Non-Langerhans cell 80, 323
Non-small cell lung cancer 78, 95
Normal tissue complication probability 79, 115
Normal tissue complications 78, 165
Normal tissue doses and complication probabilities 80, 98
Novalis™ system 81, 18
NSCLC 78, 165; 81, 163
NTCP 80, 257
Nutrition 78, 152

- Ocular adnexa 78, 6
 Oesophageal cancer 78, 236, 254
 Oligomeric proanthocyanidins 79, 45
 Oligometastases 81, 163
 Oligometastasis 81, 163
 Oncology 80, 282
 On-line correction 79, 94
 Optimization 79, 249
 Organ at risk definition 79, 259
 Organ motion 78, 27, 283; 79, 94, 335; 80, 363; 81, 284
 Organ tracking 79, 101
 Osteopontin 80, 165
 Outcome 79, 156; 81, 1, 65
 Overall treatment time 79, 142
 Oxygenation 81, 112
- Palliation 78, 101, 245
 Palliative 79, 285
 Pancreatic adenocarcinoma 81, 190
 Paranasal sinus cancer 81, 243
 Parotid sparing RT 78, 262
 Partial breast irradiation 79, 316
 Partial volume γ -radiation 79, 231
 Particle irradiation 81, 233
 Pathological complete response 78, 236
 Patient information 79, 335
 Patient positioning 80, 371; 81, 65
 Patient safety 80, 282
 Patterns of failure 78, 95
 ^{103}Pd 79, 65
 Pediatric 81, 39
 PEG 81, 196
 Pelvic radiation 79, 1
 Pelvic radiotherapy 80, 349
 Pelvic tumours 80, 349
 Pencil beam 78, 347
 Penile bulb 80, 355
 Perifosine 80, 207
 Permanent prostate brachytherapy 79, 65; 80, 57
 PET 78, 254; 80, 151; 81, 209
 PET/CT-derived target volume definition 80, 43
 Phantom 79, 190; 80, 82
 Phase I study 80, 207
 Phase II study 81, 57
 Phase II trial 79, 316
 Photon-beam treatment planning 81, 206
 Pimonidazole 80, 123, 138, 143, 157
 Pimonidazole labelling 81, 122
 Planning 78, 84; 80, 307; 81, 209
 Planning optimisation 78, 276
 Planning organ at risk volume (PRV) 80, 349
 Planning study 79, 59
 Plasma VEGF 79, 239
 Population-based 78, 131
 Portal dosimetry 81, 168
 Portal imaging 78, 199; 79, 211
 Positioning 79, 285
 Positron emission tomography 78, 254; 80, 51
 Postimplant dosimetry 81, 303
 Postimplant dosimetry 80, 378
 Preclinical 81, 112
 Preclinical research 80, 112
 Prediction 80, 236
 Prediction model 78, 339
 Predictive assays 80, 138, 223
 Predictive markers 80, 172
- Preoperative 78, 146
 Preoperative radiation 80, 172
 Preoperative radiotherapy 79, 52; 80, 4, 27
 Primary radiotherapy 78, 131
 Proctitis 78, 91
 Prognosis 79, 147
 Prognostic factors 78, 245; 79, 39
 Proliferation 78, 17
 Prophylactic liver irradiation 80, 27
 Prostate 78, 47, 199; 79, 329; 80, 378; 81, 184
 Prostate brachytherapy 81, 303
 Prostate cancer 78, 27, 36, 41, 194; 79, 1, 59, 65, 70, 94, 101, 185, 259, 341; 80, 57, 62, 78, 82, 355, 371; 81, 57, 176, 284, 291, 294
 Prostate carcinoma/cancer 79, 335
 Prostate motion 80, 73
 Prostate neoplasms 80, 69
 Prostate permanent implants 80, 296
 Prostate seed implant 79, 190
 Prostate volume 81, 179
 Protein kinase B 80, 199
 Proton beam radiation therapy 81, 243
 Proton therapy and secondary cancer 80, 263
 PRV-margin 78, 283
 PSA 80, 57
 PTV-margin 78, 283
 Pulsed dose rate 79, 75, 87; 80, 69
- Quality assurance 79, 170, 190, 208; 80, 82, 86; 81, 25, 168
 Quality control 78, 223
 Quality control procedure 81, 88
 Quality of life 78, 298; 79, 341
- Radiation 78, 84; 79, 239; 81, 47
 Radiation dose–response 79, 179
 Radiation injuries 78, 123
 Radiation morbidity 78, 123
 Radiation pneumonitis 80, 93
 Radiation pneumonopathy 81, 196
 Radiation safety 79, 65
 Radiation therapy 79, 1, 224; 80, 13; 81, 33, 57, 136
 Radiation treatment 80, 282
 Radiation treatment planning 81, 73
 Radiobiology 78, 262; 80, 257
 Radiochemotherapy 79, 80
 Radioresponse 80, 192
 Radiosensitivity 78, 17, 262
 Radiosensitization 80, 185
 Radiosurgery 80, 318
 Radiotherapy 78, 6, 91, 95, 101, 123, 152, 165, 199, 217, 245, 254, 270, 298, 326; 79, 15, 34, 39, 94, 115, 131, 147, 170, 218, 278, 285, 304, 310, 335; 80, 62, 78, 82, 93, 112, 207, 230, 307, 323, 327; 81, 39, 81, 209, 284, 315
 Radiotherapy complications 79, 45
 Radiotherapy planning 80, 69
 Radiotherapy treatment planning 78, 322
 RADPLAT 81, 143
 Random seed placement error 79, 70
 Randomised clinical trial 79, 45, 147
 Randomised controlled trial data 80, 355
 Rare 81, 39
 Rat lung 79, 231
 RBE 81, 233
 Recommendations 78, 67, 223
 Reconstruction accuracy 78, 53
 Rectal bleeding 78, 91
 Rectal cancer 79, 52; 80, 4, 27, 172

- Rectal distension 79, 59; 81, 284
 Rectal movement 79, 87
 Rectal toxicity 78, 36; 79, 341
 Rectum 78, 194; 81, 105, 294
 Recurrence 78, 306
 Reference dose 79, 298
 Regional control 79, 39
 Regional relapse 81, 136
 Reirradiation 78, 306; 81, 1
 Reproducibility 78, 339
 Respiration 80, 341; 81, 73
 Respiration surrogates 78, 339
 Respiratory motion 78, 326; 79, 122
 Retroperitoneal sarcoma 81, 81
 Review 78, 123
 Risk 80, 282
 Risk factors 79, 147
 Robotics 80, 73
 ROS scavenger 79, 231
 RT 80, 349
- SCLC 80, 307
 Second malignancy 81, 33
 Second primary 78, 306
 Seed implant 79, 70
 SEG-1 80, 185
 Segmentation of PET signals 80, 43
 Segmented multileaf collimation 80, 86
 Selectivity 78, 47
 Serum marker 80, 165
 Set-up error 78, 27, 283
 Shielding material 80, 391
 Side effects 78, 298
 Simulator 78, 84
 Single fraction 79, 278
 Small-fields 79, 348
 Soft tissue sarcoma 78, 10
 Solid tumours 80, 207
 Solid-state detectors 79, 348
 Solitary brain metastases 80, 318
 Sonarray 81, 176
 Spatial accuracy 81, 25
 Sphincter preservation 80, 4
 Squamous cell anal canal carcinoma 79, 75
 Squamous-cell 79, 34
 Staging 79, 21
 Stent implantation 78, 60
 Step-and-shoot 79, 162
 Stereotactic 79, 348
 Stereotactic body radiation therapy 81, 264
 Stereotactic irradiation 81, 97
 Stereotactic radiosurgery 81, 25
 Stereotactic radiotherapy 79, 109; 81, 18
 Stereotactical therapy 80, 268
 Submandibular gland 78, 270
 Superoxide dismutase 81, 196
 Superposition 81, 309
 Superposition/convolution 81, 250
 Supine position 78, 217
 Supra clavicular lymph nodes 79, 310
 Surface Marking 78, 84
 Surface registration 79, 170
 Surgery 78, 298; 80, 318; 81, 33
 Survival 79, 239
- Systematic review 80, 13
 Systemic palliative treatment 80, 313
- Tapping 80, 73
 Target definition 79, 259
 Target volume 80, 341
 Taxonomy 80, 282
 Temporal resolution 80, 341
 Temporary prostate implants 80, 69
 TGF- β 78, 17; 81, 196
 The Netherlands 78, 131
 Thoracic radiation 81, 196
 Three-dimensional 78, 84
 Three-dimensional conformal radiotherapy 78, 322
 Threshold definition 80, 43
 Time to treatment failure 79, 239
 Tirapazamine 78, 138
 Tissue inhomogeneity 79, 203
 Tomotherapy 78, 276, 313
 Toxicity 78, 298; 79, 59; 81, 143, 151
 TP53 mutations 80, 230
 TRAIL 80, 214
 Transrectal ultrasound (TRUS) 81, 179
 Treatment planning 78, 27, 53, 67, 207, 313; 79, 115, 198; 81, 269
 Treatment planning and optimisation 78, 169
 Treatment planning systems 79, 208; 81, 315
 Trends 78, 131
 Tumor 78, 138; 81, 112
 Tumor motion 78, 339; 81, 73
 Tumor xenografts 80, 185
 Tumour hypoxia 80, 165
 Tumour oxygenation 80, 123
 Tumour stem cells 80, 112
- Ultrasound 81, 65
 Ultrasound positioning system 81, 176
 Univariable analysis 81, 143
 Urethral bulb 80, 355
 Urinary bladder 80, 250
 Urinary bladder cancer 80, 98; 81, 276
 Uroplakin III 80, 250
 Urothelial barrier 80, 250
 Uterine cervix carcinoma 80, 123
- Vasculature 78, 138
 Verification 79, 109, 224; 80, 385
 Verification of intensity modulated radiation therapy 78, 332
 4 versus 6 MV X-ray irradiation 79, 203
 Visceral blood supply 81, 190
 Volume changes 79, 304
 Volume effect 79, 115
 Voxel intensity 79, 249
- Weekly cisplatin 81, 9
 WHO classification 79, 179
 Whole brain irradiation 80, 318
 Whole brain radiotherapy 80, 313
 Whole pelvic irradiation 80, 19
 Wound healing 78, 17
- Xenograft 80, 214
 Xerostomia 78, 262, 270
 Xerostomia 81, 151
- 4-year follow-up 80, 57